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Introduction 1
1 INTRODUCTION AND OBJECTIVES 
 
Endogenous retroviruses and related elements are an integral part of the genome of many 
organisms, including primates and humans. Around 8% of the human genome is derived 
from retrovirus-like elements (Smith, 1999). They originate from ancient retroviral 
infections or are relics of transposomal activity in the germ-line cells (Paces et al., 2002).  
 
Human endogenous retrovirus long terminal repeats (HERV-LTRs) are represented with 
52.7 Mb (1.8%) in the human genome. These sequences contain all the signal structures 
required for the regulation of gene transcription, such as promoters, enhancers and 
transcription factor binding sites (Majors, 1990; Brosius, 1999; Schoen, 2001). They thus 
represent an enormous resevoir of regulatory sequences within the human genome. Could 
this potential of HERV-LTRs be utilized for regulation of therapeutic genes? To ensure 
efficiency of gene therapy, promoters that regulate therapeutic genes have to be highly 
active to create large numbers of transcripts in the target cell and also to compensate low 
efficiency of gene delivery systems. For safety reasons, tissue- or cell-type specificity of 
the promoter is desirable. 
 
Two HERV LTRs were chosen on behalf of these criteria: HERV-L which showed high 
promoter activity and specificity in vitro and HERV-H-H6 which showed high promoter 
activity in vitro. The objective of the investigations reported here was to study expression 
level and pattern of these HERV-LTRs in vivo through the establishment of transgenic 
mouse models: HERV-L was cloned into a luciferase expression vector and HERV-H-H6 
into an EGFP expression vector. Gene constructs were injected into the pronuclei of 
zygotes. Transgenic mice were examined for integration of the injected gene construct 
and for expression of the corresponding reporter gene in various tissues. While the pBL-
HERV-L construct was not active in transgenic animals, pEGFP-HERV-H-H6 was 
expressed in selected organs. To consider species-specific effects, pEGFP-HERV-H-H6 
and pBL-HERV-L were also used to generate transgenic rabbits. This work will be 
presented in the dissertation of Zoltan Hubbes at the Department for Molecular Animal 
Breeding/LMU Munich. 
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2 REVIEW OF THE LITERATURE 
 
2.1 Genetic engineering of the mouse 
 
2.1.1 Transgenic technology 
 
Transgenesis, or the stable integration of foreign DNA into the host genome, has 
developed into one of the most powerful techniques for analysing gene function and 
regulation (Hammes and Schedl, 2000). Transgenic animals have recently been defined 
by Beardmore (1997) as: “organisms containing integrated sequences of cloned DNA 
(transgenes), transferred using techniques of genetic engineering (including those of gene 
transfer and gene substitution)”. There are several techniques for the production of 
transgenic animals. The most commonly used methods are pronuclear DNA 
microinjection and embryonic stem (ES) cell manipulation. Other possibilities are nuclear 
transfer (NT), cytoplasmatic DNA injection, use of viral vectors, manipulation of 
primordial germ cells and sperm-mediated gene transfer (Mepham et al., 1998; Wolf et 
al., 2000). Consequences of gene transfer can include “gain of function” or “loss of 
function” phenotypes. Potential and actual applications of transgenic animals were 
summarized by Gordon (1996) as follows: 
• Basic research 
• Disease models 
• Vaccine testing 
• Toxicity testing 
• Xenotransplantation  
• Gene farming (production of therapeutic proteins) 
• Manipulation of livestock production traits 
The first transgenic animals that were generated were mice (Gordon et al., 1980). Since 
then, gene transfer has been established not only in mammalian species such as cattle, 
sheep, rabbits, goats, rats and pigs but also in fish and poultry (Brem et al., 1985; 
Campbell et al., 1996; Chen et al., 1996; Kubisch et al., 1997; Chan et al., 1998; Hong et 
al., 1998; Baguisi et al., 1999; Zakhartchenko et al., 1999).  
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2.1.2 Mouse models in genetics 
 
Mice have become the mammalian model of choice for the application of genetics in 
biomedical research due to the evolutionary conservation of physiological systems and 
their attendant pathologies among all mammals as well as the exceptional power of 
genetic research technologies in this species (Paigen, 2002). Features of mouse 
reproduction physiology like short generation time (10 weeks from being born to giving 
birth), prolifical breeding in the lab (5-12 pups), immediate postpartum oestrus and 
deposition of a vaginal plug (for timing of pregnancies) reinforce this position (Silver, 
1995). Until the 1980s, biomedical studies involving alteration of the mouse genome had 
to rely either on the appearance of spontaneous mutations or on the generation of 
chemically- and radiation-induced mutations and allophonic mice. These studies played a 
major role in biomedical research of the last century (Jonas, 1984). The discovery of the 
severe combined immunodeficiency (SCID) mouse became well known as model for a 
corresponding human disease (Custer et al., 1985). In 1981 Margaret C. Green listed 
hundreds of mouse strains and mutants attesting to the rich biological material available 
through genetic studies on mice. 
 
Thus, when recombinant DNA methods merged with mammalian cell culture and embryo 
manipulation techniques in the 1980s, the mouse was the laboratory species most suitable 
for modern genetic engineering. Two mouse models played a major role in this 
development: 
• Transgenic mice result from the introduction of either endogenous or exogenous gene 
sequences into the mouse genome by pronuclear injection. Subsequent 
overexpression of endogenous genes or expression of novel gene products, i.e. “gain 
of function “, is one possible phenotype. “Loss of function” is another possible 
phenotype resulting from insertional mutagenesis by the transgene. Targeted 
inhibition of gene activity can be achieved in transgenic mice by expression of 
antisense RNA (Katsuki et al., 1988; Pepin et al., 1992) or by dominant negative 
mutations (Hagenfeldt-Johansson et al., 2001). 
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•  Knockout mice can be generated by directed mutagenesis in embryonic stem cells. 
When endogenous genes are disrupted, “loss of function “ of a defined endogenous 
gene is the resulting phenotype. The use of site specific Cre and Flp recombinases in 
gene targeting allowed the generation of conditional knock-outs, i.e. animals in 
which a gene knock-out is restricted to specific tissues (Lakso et al., 1992) or occurs 
in response to an exogenous induction signal (Metzger et al., 1995).  
 
Over the last decade, many transgenic and knockout mutant mouse strains have been 
created. Models like Prnp knockout mice (Bueler et al., 1992) which play an essential 
role in TSE (Transmissible Spongiform Encephalopathy) research or the popular “green 
mice” generated by Okabe et al. (1997), illustrate the importance of genetically 
engineered mouse strains. They are documented in transgenic databases such as TBASE 
(Woychick et al., 1993) or Induced Mutant Resource (IMR) (Davisson, 1990): 
www.tbase.jax.org; www.jaxmice.jax.org/index.shtml. 
 
Complementary to these “gene driven” approaches, in which mouse models are 
produced for those genes that we already know, the large-scale Munich ENU-mouse 
mutagenesis screen (Hrabe de Angelis and Balling, 1998; Rathkolb et al., 2000), which 
is part of the German Human Genome Project, offers a “phenotype driven” approach. 
What at first sight, appears to be solely a come-back of a well established technique for 
chemical mutagenesis (Russell et al., 1979), offers in fact in combination with current 
possibilities of genetic analysis a new dimension of functional genome analysis. In 
different mouse mutants that display one disease phenotype, the responsible mutated 
genes are identified. The study of divers mouse mutants with one phenotype but 
mutations in different genes is especially interesting for the understanding of 
pathogenesis of the corresponding disease. The mutant lines are freely accessible to non-
commercial users. The strains are indexed under http://www.gsf.de/ieg/groups/ 
enu/mutants/index.html. 
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2.1.3 Transgenic mice 
 
The classical method, generation of transgenic mice by microinjection of DNA solution 
into the male pronucleus of fertilized oocytes, is described in detail in the corresponding 
manuals (Hogan et al., 1994; Pinkert, 1994). This method has remained basically 
unchanged since its development 20 years ago (Gordon and Ruddle, 1981). As donors for 
fertilized oocytes C57BL/6 x SJL hybrid mice have been shown to be more efficient than 
C57BL/6 mice. They delivered more fertilized oocytes, the percentage of eggs that 
survived injection and developed into pups was higher as well as the percentage of mice 
that retained the microinjected DNA (Brinster et al., 1985). After successful delivery of 
the DNA, the transgene integrates into the mouse genome and replicates with the 
endogenous chromosome. For a standard transgene, integration of 1-50 copies is normal, 
but integration of up to 1000 copies has been observed (Lo et al., 1987). The individual 
copies can be found in tandem arrays as head-to-tail fusion but also as head-to-head or 
tail-to-tail fusion. If transgene integration occurs at more than one site, the offspring of 
the transgenic founder are likely to carry only a subset of the copies integrated in the 
founder animal, due to segregation of chromosomes. In 10-30% of transgenic animals, 
integration does not occur during the one-cell stage, but later in development. As a 
consequence, the resulting mice will be mosaics and germ line transmission (Gordon and 
Ruddle, 1982) is not guaranteed. Transgenic mice of generation F0, so called founder 
mice, are hemizygous for the transgene (Wagner et al., 1983). Non mosaic founders with 
one integration site will pass on the transgene to 50 % of their offspring (Gannon et al., 
1990). To eliminate doubts about mosaicism and genetic variability of the founders, F0 
transgenic mice are mated with non-transgenic inbred mice. Expression studies are 
carried out from the F1 generation on. 
 
The described characteristics of integration of the transgene already indicate the main 
problem of DNA microinjection: integration occurs randomly. Levels and spatial 
distribution of transgene expression are highly sensitive to transcriptional activators or 
silencers located in the vicinity of the integration site. This can lead to reduced, abolished 
or ectopic expression, a phenomenon called position effect. As position effects can 
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influence expression of the transgene, it is important to generate and examine several 
independent transgenic lines and to compare their phenotypes (Hammes and Schedl, 
2000). A second negative aspect of random integration is that insertion of the transgene 
can occur within an endogenous gene, creating an insertional mutation and disrupting the 
locus. This can result in a distinct phenotype, especially in homozygous transgenic mice 
(Wagner et al., 1983). Another limitation of the DNA microinjection technique is that the 
number of integrated copies at one site can not be influenced. The presence of multiple 
copies integrated at a single site as concatemer has been shown to reduce the level of 
expression of the gene construct independently of the integration site (Garrick et al., 
1998). Furthermore, the level of transgene expression can be negatively influenced by 
DNA methylation (Jaenisch, 1997). DNA methylation of endogenous genes is associated 
with the phenomenon of genetic imprinting. This modification of genetic information 
plays a decisive role in mammalian development when maternal and paternal genome 
have to contribute to embryonic development (Reik et al., 1987). 
 
2.1.4 Design of the gene construct 
 
Apart from the integration process, the design of the gene construct itself has major 
influence on its expression level and pattern. The DNA element to be transcribed can be 
complete or partial cDNA, or a genomic sequence. The transgene is cloned downstream 
of a suitable promoter element which may determine expression level and pattern. 
Including an intron downstream of a transcription start site has been shown to improve 
expression (Choi et al., 1991; Palmiter et al., 1991). A start codon preceded by a Kozak 
consensus sequence can also enhance expression (Kozak, 1987). Additionally, it has been 
demonstrated that efficient expression of a transgene requires polyadenylation of the 
transcribed product, for this reason it is advisable to clone a polyadenylation signal, e.g. 
from SV 40 or polyoma virus at its 3`end. Plasmid sequences flanking the transgene have 
shown to negatively influence expression (Chada et al., 1985).  
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In addition to the core techniques described above, further approaches have been made 
recently. To reduce position effects, transgenes consisting of large (>50kb) genomic 
fragments, can be obtained from yeast artificial chromosomes (YACs) (Chevillard et al., 
2002), bacterial artificial chromosomes (BACs) and P1-derived artificial chromosomes 
(PACs). Another approach to enable position independent expression of transgenes is the 
use of matrix attachment regions (MARs) or scaffold attachment regions (SARs) (Mc 
Knight et al., 1996). Also conditional transgenic technologies (reviewed in Ryding et al., 
2001) like the tetracycline transactivator system (Bujard and Gossen, 1992) and the 
ecdysone induction system (No et al., 1996, Saez et al., 2000) have been shown to be 
reliable tools for regulated transgene expression.  
 
2.2 Human endogenous retroviruses 
 
2.2.1 Characteristics and biological significance of human endogenous retroviruses  
 
Approximately 2.7% (78.9 Mb) of the human genome consist of proviral structures called 
human endogenous retroviruses: HERVs (Smit, 1999). These proviruses most probably 
originate from primary infections of germ line cells by ancient retroviruses. In some cases 
they were amplified by retrotransposition or reinfection in the course of evolution 
(Wilkinson et al., 1994; Löwer et al., 1996; Parseval et al., 2001) as presented in Figure 
1. The current HERV database contains 39 HERV families colinear with the typical 
retroviral genome: LTR-gag-pol-(env)-LTR. 1.8% (52.7 Mb) of the human genome is 
derived from HERV-LTRs and 0.9% of the genome (26.2 Mb) are internal HERV 
sequences (Paces et al., 2002). A proviral long terminal repeat (LTR) contains the 
functional regions U3, R and U5. U3 and U5 are unique sequences derived from the 3´ 
and 5´ ends of the viral RNA, while R is a short sequence present at both termini of the 
RNA genome. The strongest viral transcriptional enhancer sequences are typically found 
in U3 as are promoter signals such as the TATAA box (Feuchter and Mager, 1990; 
Majors 1990). The structural genes are gag, which codes for the proteins of the viral 
capsid, pol which codes for the viral enzyme reverse transcriptase, integrase and protease 
and env which codes for a transmembrane glycoprotein and the surface protein 
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(Wilkinson et al., 1994). HERVs are classified according to sequence homologies, but the 
nomenclature is not yet stabilized (Parseval et al., 2001). 
 
 
 
Figure 1: Life cycles of endogenous retroviruses in comparison to exogenous 
retroviruses modified from Löwer et al. (1995) 
 
Different elements of these proviruses play a role in physiological as well as in 
pathological processes. HERV LTRs can serve as transcription regulators, alternative 
promoters and polyadenylation signals for cellular genes. A LTR sequence of the HERV-
E family is involved in the tissue-specific expression of human salivary amylase. The 
insertion of this HERV element upstream of the human amylase gene complex is 
correlated with a change from pancreatic to parotid expression (Samuelson et al., 1988). 
In the human cytochrome c1 gene, part of a HERV-I LTR was found to be involved in 
transcriptional regulation (Suzuki et al., 1990). A HERV-H LTR is reported to promote 
the expression of a protein related to phospholipase A2 by intergenic splicing of two 
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adjacent human genes (Feuchter et al., 1993; Kowalski and Mager, 1998; Kowalski et al., 
1999). A HERV-H LTR seems to be involved in the regulation of the ICOS gene 
(Inducible T-cell CO-Stimulator) on the human chromosome 2q33, which plays an 
important role in autoimmune diseases (Ling et al., 2001). A possible involvement of 
LTR 13, in association with certain DQB 1 alleles (genes of the major histocompatibility 
complex) in type I diabetes (IDDM) was suggested by Pascual et al. (2001). 14 complete 
HERV-K LTRs are scattered all over chromosome 19, all in vicinity (<100 bp) of zinc-
finger related genes (Vinogradova et al., 1997), while HERV-R is reported to regulate 
expression of the human Krüppel-related zinc finger gene (H-plk) in different organs 
such as placenta, adrenal cortex and testis (Kato et al., 1990; Abrink et al., 1998).  
 
Examples for activity of other HERV elements within the human genome are described 
as well. The HERV-W env gene on chromosome 7 encodes syncytin: a protein essential 
for the formation of the syncytiotrophoblast layer of the placenta (Blond et al., 2000; Mi 
et al., 2000). In patients with multiple sclerosis, AIDS and Alzheimer´s dementia with 
concomitant elevated TNF-alpha levels, HERV expression was found in monocytes and 
brain tissue (Johnston et al., 2001). HERV-H envelope genes are associated with 
immunosuppressive properties (Mangeney et al., 2001; Parseval et al., 2001). The 
presence of autoantibodies crossreacting with retroviral gag proteins can be associated 
with the autoimmune disease Lupus erythematodes (Hishikawa et al., 1997). HERV-
RNA can be found in cerebrospinal fluid of patients suffering from schizophrenia 
(Karlsson, 2001). Retrovirus-like particles are expressed in steriod-dependent manner in 
the human mammary carcinoma cell line T47D (Ono et al., 1987; Seifarth et al., 1995; 
Seifarth et al., 1998). HERV-K RNA expression is detectable in teratocarcinoma, i.e 
germ cell tumor cell lines (Löwer et al., 1993). Most patients with germ cell tumors, 
seminomas as well as ovarian germ cell tumors, display antibodies against HERV-K gag 
and env proteins (Herbst et al., 1998; Boese et al., 2000). High level expression of 
HERV-R in the adrenal cortex as well as in the placenta was described by Katsumata et 
al. (1998). 
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2.2.2 In vitro and in vivo models for testing promoter activity of HERV-LTRs  
 
Promoter activity and specificity of isolated HERV LTRs in heterologous reporter 
systems have been investigated in various cell culture models. Data is indicating that 
HERV-LTRs drive expression of reporter genes in celltype-specific manner. Table 1 
gives an overview on studies testing HERV LTR promoter activities in vitro. A single in 
vivo model has been published so far: the endogenous retroviral like element AMY1C, 
associated with the human salivary amylase gene complex, drove expression of a reporter 
gene in transgenic mice exclusively in the parotidea (Ting et al., 1992).  
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Table 1: In vitro models for gene regulation by HERV LTRs in different cell types 
 
LTR promoter Activity Cell type Reporter  Reference
 
HERV-H-H6  
 
HERV-H-5´R2  
HERV-H-3`R1  
HERV-H-N10-14  
HERV-H-PB-3  
 
 
high activity in NTera2D1. 293, 
Hep2,COS-1 and NIH3T3; 
activity in COS-1; 
no activity; 
low activity in NTera2D1 and 293; 
activity in COS-1. 
 
NTera2D1:human 
teratocarcinoma cell line; 
293: human embryonal 
kidney cell line; Hep2: 
human adenocarcinoma cell 
line; NIH 3T3: mouse cell 
line; COS-1: monkey 
kidney cell line. 
 
 
Chloramphenicol 
acetyltransferase 
assay 
 
Feuchter and 
Mager, 1990 
HERV-K Class I 
HERV-K Class II 
HERV-K Class III 
HERV-K Class IV 
high relative activity 
low relative activity 
high relative activity  
lowest relative activity  
 
- In vitro 
transcription assay 
(32P-UTP) 
 
Mold et al., 
1997 
HERV-K-T47D 
 
HERV-K-PI167 
 
 
HERV-L 
 
 
HERV-E 
 
HERV-H-H6 
 
HERV-T 
 
 
around 25% rel activity in HaCaT and 
Hela;  
relative activity under 4% in all lines 
tested; 
250% rel. activity only in HaCaT; 
 
relative activity under 2% in all lines 
tested; 
relative activity from 20% to 100% in 
all lines tested; 
relative activity under 5% in all lines 
tested. 
LC5: human lung fibroblast 
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2.2.3 Characteristics and biological significance of the HERV-H-H6 LTR 
 
The HERV-H family is one of the most widely represented among human endogenous 
retroviruses, with approximately 1,000 elements per haploid genome (Mager and 
Henthorn, 1984). Since they are present in the genome of New World monkeys, they are 
supposed to have entered the primate genome >40 million years ago. However, the 
majority of the HERV-H elements result from later expansion 30-35 million years ago 
(Mager and Freeman, 1995; Andersson et al., 1997). Expression of HERV-H elements 
was detected at low level in lung (Lindeskog et al., 1993) and peripheral blood 
mononuclear cells (Medstrand et al., 1992; Lindeskog et al., 1993; Kelleher et al., 1996) 
and at high level in normal placenta (Wilkinson et al., 1990). Significant amounts of 
HERV-H transcripts were also expressed in tumor cell lines, mainly bladder carcinomas, 
teratocarcinomas, testicular tumors and lung tumors (Wilkinson et al., 1990; Hirose et al., 
1993). Only 10 % of the HERV-H proviruses are structurally intact with full length gag, 
pol and env domains interrupted by several stop codons and a total size of 8.7 kb. The 
majority is partially deleted and only about 5.8 kb long (Hirose et al., 1993; Wilkinson et 
al., 1993). 
 
HERV-H-H6 is a member of the HERV-H family. Its LTR was first isolated by Feuchter 
and Mager (1990) from a Hep2 cDNA clone. Hep2 cells represent a subline of HeLa 
(human cervical adenocarcinoma) cells. Schoen et al. (2001) selected two active LTRs, 
HERV-H-CL1 type Ia and HERV-H-CL4 type Ia, from Chang liver cells (human liver 
cells) by a pol-expression array combined with RT-PCR. They proved to be 100% 
identical to the HERV-H-H6 LTR described by Feuchter and Mager (1990). Sequence 
data was deposited by Schoen et al. with the EMBL/GenBank Libraries under Accession 
number AF 315090. Fasta search in the HERVdatabase revealed 99.7% identity of AF 
315090 with rv_062672 located on the human chromosome 13. This suggests that 
HERV-H-H6 is localized on the human chromosome 13. 
 
The following structures were identified on the HERV-H-H6 LTR by Schoen et al. 
(2001): type I repeat, type II repeat and a unique region. In addition, the HERV-H-H6 
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LTR contains a GC-rich region downstream of the TATA box. This region has been 
identified in all HERV-H LTRs of type I and Ia characterized so far (Sjottem et al., 1996; 
Anderssen et al., 1997). It was found to contain binding sites for the transcription factors 
Sp1 and Sp3, which may be involved in the tissue-specific expression pattern of HERV-
H elements (Nelson et al., 1996; Sjottem et al., 1996). Blast search revealed the presence 
of the steroid-regulatory sequence TGTTCT, which is also part of the HERV-R LTR. 
High level expression of HERV-R in the adrenal cortex is possibly related to steriod 
production in adrenocortical cells (Katsumata et al., 1998). 
 
The HERV-H-H6 LTR has been tested for promoter activity in heterologous systems by 
two in vitro studies so far: Feuchter and Mager (1990) investigated the HERV-H-H6 LTR 
by chloramphenicol acetyltransferase assay and Schoen et al. (2001) examined the LTR 
by luciferase assay. Feuchter and Mager (1990) described strong promoter activity of the 
HERV-H-H6 LTR in human (NTeraD1, 293, Hep2), monkey (COS-1) and mouse (3T3) 
cells. Schoen et al. (2001) described strong relative promoter activity in human LC5 and 
U373 cells (100% and 70% respectively) and weaker relative promoter activity in human 
MiaPaCa2 (20%), 85HG66 (10%), ChangLiver (50%), HaCaT (30%), Hela (15%) and 
MCF7 (25%) cells. Relative promoter activity was standardized with the cotransfected 
plasmid pRL-TK (Promega), which contained the thymidine kinase promoter upstream of 
the renilla luciferase gene. 
 
2.2.4 Characteristics and biological significance of the HERV-L LTR 
 
Within the human genome, a group of 200 moderately reiterated elements, named 
HERV-L elements, was identified (Cordonnier et al., 1995). Disclosing similarities in 
their pol gene with the foamy retroviruses suggest a role as evolutionary intermediate 
between classical retrotransposons and infectious retroviruses. HERV-L are present 
among all placental mammals, suggesting that they were already present at least 70 
million years ago (Bénit et al., 1999). The complete nucleotide sequence (6,591 bp) of 
one of these elements was determined from a PCR product of reverse-transcribed RNA 
from human placenta. It was termed HERV-L because primers were complementary to 
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leucine tRNA (Cordonnier et al., 1995). The complete HERV-L sequence was deposited 
by Cordonnier et al. (1995) with the EMBL/GenBank Library under the accession 
number X89211. HERV-L is characterized by the following features: bordered by LTRs, 
presence of gag and pol genes and of a dUTPase region, absence of the env gene (Bénit et 
al., 1999). The coding regions gag and pol contained several stop codons, indicating that 
the cloned HERV-L element could not code for a functional gene product (Cordonnier et 
al., 1995). HERV-L contains a distinct region disclosing 53% homology to a mouse 
mammary tumor virus sequence (Moore et al., 1987), which has been identified as 
dUTPase. A dUTPase sequence is found in type B and D oncoviruses, in nonprimate 
lentiviruses, in poxviruses and in herpesviruses (Mc Geoch, 1990). 
 
The 5´ and 3´ LTRs are 82% identical (i.e. 462 identical bp). They are flanked by short 
inverted repeats (TGA...ACA). They contain a CAT box, a TATA box and a 
polyadenylation signal. Screening the LTR reveals the presence of a two AP-1 binding 
sites (Cordonnier et al., 1995; Leib-Mösch, 2000). AP-1 contributes to keratinocyte-
specific expression of the human profiaggrin gene (Maurer et al., 1991). Two CACACCC 
motives were identified as indirect repeats within the HERV-L LTR. They are 
characteristic motives of the keratinocyte-specific EBV ED-L2 promoter and other 
keratinocyte-specific promoters (Leib-Mösch, 2000). Fasta search in the HERV database 
revealed 99.5% identity of the HERV-L LTR (X89211; nucleotide 2-397) with 
rv_071357 on human chromosome 16. The HERV-L LTR was tested for promoter 
activity in heterologous systems by Schoen et al. (2001). The LTR was examined by 
luciferase assay in different cell lines. Strong relative promoter activity (270%) was 
measured only in human HaCaT cells. In all other cell lines tested the relative promoter 
activity was weak (< 29%). Relative promoter activity was standardized with the 
cotransfected plasmid pRL-TK (Promega), which contained the thymidine kinase 
promoter upstream of the renilla luciferase gene. 
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2.2.5 Potential use of HERV-LTRs in gene therapy 
 
Gene therapy involves the transduction of an active gene that may either be a functional 
homolog of a defective gene, or a nonrelated therapeutic gene (Salmons and Günzburg, 
1993). Presently available gene delivery vehicles can be divided into two categories: viral 
and nonviral vectors. The nonviral vectors, also referred to as synthetic gene delivery 
systems, rely on direct delivery of either naked DNA or a mixture of DNA with 
liposomes. Viral vectors can be subdivided into two categories: a) integrating vectors, 
like retroviral and adeno-associated viruses and b) nonintegrating vectors, like modified 
adeno-associated viruses (Pfeifer and Verma, 2001). Major drawbacks of gene delivery 
systems are the efficiency and the safety of gene transfer. High expression level of 
therapeutic genes in the target cell and a distinct expression pattern in the organism are 
prerequisites for succesful clinical applications.  
 
As vehicles in gene therapy, standard retroviral vectors can integrate into the host 
genome of the infected cell and deliver therapeutic genes. As consequence of the reverse 
transcription of the retroviral single-stranded RNA into double-stranded DNA in the 
infected cell, the U3 region of the LTR is duplicated and one copy is located at the 5´end 
of the provirus (Saller et al., 1998). The U3 region carries retroviral promoter and 
enhancer elements which control gene expression of the provirus (Yu et al., 1986). There 
is evidence that heterologous promoters, inserted into retroviral vectors to target 
expression, may interact with retroviral U3 sequences and influence the expression of 
therapeutic genes negatively (Wu et al., 1996). This problem can be avoided using 
Promoter Conversion (ProCon) retroviral vectors (Mrochen et al., 1997). ProCon vectors 
carry a heterologous promoter instead of the U3 region. After reverse transcription in the 
target cell, this heterologous promoter can control expression of the provirus. As HERV 
LTRs may exhibit tissue specific promoter activity, it might be interesting to insert them 
into ProCon vectors to control expression level and pattern of therapeutic genes. A 
comparison of the integration of standard retroviral vectors into infected cells to the 
integration of ProCon vectors is presented in Figure 2. 
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Figure 2: Reverse Transcription of retroviral single-stranded RNA to proviral 
double-stranded DNA in the infected cell. Comparison between a standard retroviral 
vector and a ProCon vector. R: repeat; U5: unique region 5´end; U3: unique region 
3´end; P: heterologous promoter; TG: therapeutic gene; gag, pol, env: genes coding for 
retroviral enzymes. 
 
Apart from genetic diseases, various forms of cancer and infective diseases, e.g. HIV are 
major targets for gene therapy (Salmons and Günzburg, 1993). Current clinical studies of 
gene transfer in humans, sorted by disease, are available under: 
http://www4.od.nih.gov/oba/rac/clinicaltrial.htm. Current clinical studies sorted by 
therapeutic genes are available under: http://137.187.206.75/oba/rac/gtbfgrep.htm. 
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2.3 The use of Green Fluorescent Protein (GFP) as reporter gene 
 
In 1997 the popular german newspaper Bild reported: „Forscher züchten grüne 
Leuchtmäuse“ (scientists bred green, luminescent mice). This piece of news based on a 
publication by Okabe et al. (1997) in the FEBS Letters. They had generated transgenic 
mice with the reporter gene enhanced green fluorescent protein (EGFP) under the control 
of the chicken beta-actin promoter, a cytomegalovirus enhancer, a beta actin intron and 
the bovine globin poly-adenylation signal. All tissues from these transgenic mice, with 
exception of erythrocytes and hair, looked green under excitation light (Figure 3). In a 
short period of time, the GFP from the jellyfish Aequorea victoria had vaulted from 
obscurity to become one of the most widely studied and exploited proteins in cell biology 
and biotechnology (Tsien, 1998). 
 
 
Figure 3: EGFP expression, visible to the naked eye under 360 nm UV light (Okabe 
et al., 1997). 
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2.3.1 The discovery of GFP 
 
The green fluorescent protein was discovered by Shimomura et al. (1962). When they 
described isolation and purification of the aequorin protein from the Aequorea jellyfish 
he mentioned another substance: “a protein giving solutions that look slightly greenish in 
sunlight, though only yellowish under tungsten lights, and exhibiting a very bright, 
greenish fluorescence in the ultraviolet of a mineralite, has also been isolated from the 
squeezates.” The emission spectra of the aequorin protein and the “green protein” were 
published shortly after (Johnson et al., 1962). The luminescence of the “green protein”, 
later termed GFP, peaked at 508 nm. Chemiluminescence of aequorin emitted blue light 
of a broad spectrum that peaked near 470 nm, which was close to one of the excitation 
peaks of GFP. The blue emission of aequorin was thus converted by GFP to the green 
glow in the intact animals. The same principle of color shift was discovered in related 
coelenterates containing GFP: in Obelia (hydroid), Renilla (sea pansy), Phialidium 
(jellyfish), Mitrocoma (jellyfish), Cavernularia (sea cactus), Dicosoma (sea anemone) 
and Ptilosarcus (sea pen) (Morin and Hastings, 1971; Ward, 1979; Tavaré et al., 2001). 
Apart from Aequorea GFP, only Renilla GFP has been well characterized (Ward, 1979). 
In the following, GFP refers to the Aequorea species except where another genus name is 
specifically indicated. 
 
2.3.2 Structure of GFP and Enhanced Green Fluorescent Protein (EGFP) 
 
The wildtype (wt) gfp 10 gene was originally cloned and sequenced from cDNA by 
Prasher et al. (1992) (GenBank accession No. M62653). Nucleotide sequences derived 
from Aequorea cDNA or exons indicated another 4 variants (Genbank accession No. 
L29345, X83959, X83960 and M62654). The variants generally differed by conservative 
amino acid replacements, suggesting that they might have nearly identical physical 
properties. In 1994, two groups showed that expression of cloned wt GFP in prokaryotes 
(Escherichia coli) and in eukaryotes (Caenorhabditis elegans) created fluorescence 
(Chalfie et al., 1994; Inouye and Tsuji, 1994). The gene contained all information 
necessary for the synthesis of the chromophore. No jellyfish-specific enzymes were 
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necessary for the synthesis of the chromophore. No jellyfish-specific enzymes were 
Review of the literature 19
necessary for posttranslational processing. This led to extensive activity describing the 
use of wt-GFP (Cubitt et al., 1995). Limitations soon became obvious: 
photoisomerisation and autofluorescence when excited at the major peak i.e. 395 nm 
(Cubitt et al., 1995), slow formation of the chromophore (Heim et al., 1995) and 
precipitation in the cytoplasm as insoluble inclusion bodies. To overcome these 
deficiencies, various strategies have been used to generate and screen mutants of GFP 
(for review see Tsien and Prasher, 1998).  
 
Cormack et al. (1996) identified the EGFPmut1 (F64L, S65T) in GFP transformed 
bacteria by fluorescence-activated cell sorting (FACS) analysis: GFP had been mutated 
by randomization of a predetermined, limited stretch of amino acid residues. 
Transformed bacteria had been screened by FACS analysis for increased brightness at 
488 nm excitation light. The commercially available EGFP (Clontech, Palo Alto, CA) is 
based on the EGFPmut1 (F64L, S65T). In the EGFPmut1, insertion of the amino acid 
leucine at position 64 improved protein folding at 37°C, whereas the mutation of serine 
65 to threonine promoted chromophore ionization. EGFP from Clontech is furthermore 
characterized by an optimal nucleotide sequence for translational initiation (Kozak, 1989) 
and a presumably neutral mutation of histidine 231 to leucine. The EGFP nucleotide 
sequence (4,151 bp) was deposited at GenBank under accession number CVU55761. 
 
The GFP chromophore is a p-hydroxybenzylideneimidazolinone (Figure 4) formed from 
the residues 65-67 which are serine, tyrosine and glycine in the native protein (Prasher et 
al., 1992; Cody et al., 1993). The chromophore is formed by a cyclization reaction and an 
oxidation step that requires molecular oxygen (Cubitt et al., 1995). 
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Figure 4: Structure of the GFP chromophore as proposed by Shimomura (1979) 
 
Although GFP was cristallized in 1974 (Morise et al., 1974), the secondary, tertiary and 
quaternary structure were first solved in 1996 (Yang et al., 1996; Ormö et al., 1996). 
Under Protein Data Bank accession number 1EMA and 1GFL the amino acid sequence 
(236 amino acids) is provided. GFP is an 11-stranded ß-barrel threaded by an α-helix 
running up the axis of the cylinder. The chromophore is attached to the α-helix and is 
buried in the center of the cylinder: the so-called ß-can (Phillips, 1997). 
 
2.3.3 Biochemical and physical properties of EGFP 
 
As a result of the chromophore mutation (serine 65 to threonine) in EGFP the GFP´s 395 
nm excitation peak, due to the neutral phenol, is suppressed and the excitation peak, due 
to the phenolate anion (Figure 5) is enhanced five to six fold in amplitude and shifted to 
488 nm (Cormack et al., 1996). The EGFP emission spectrum peakes at 507 nm. 
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Maturation of the chromophore is about fourfold faster in EGFP than in GFP (Heim et 
al., 1995). Fluorescence is only emitted when the molecules have folded properly and 
remain in an oxidized state. Misfolded, reduced or fully denatured proteins are not 
fluorescent. To improve folding at 37°C, i.e. above jellyfish temperature, EGFP contains 
leucine at position 64 (Cormack et al., 1996). EGFP needs to be in an oxidized state to 
fluoresce because chromophore formation is dependent upon oxidation of Tyr-66. Strong 
reducing agents, such as 2 mM FeSO4 or 5 mM Na2S2O4, convert EGFP into a 
nonfluorescent form (Inouye and Tsuji, 1994). Fluorescence can be fully recovered after 
exposition to atmospheric oxigen. Weaker reducing agents, such as 2% ß-
mercaptoethanol or 10 mM dithiothreitol (DTT), do not affect the fluorescence of EGFP 
(Inouye and Tsuji, 1994). EGFP retains its fluorescence in mild denaturants, such as 1% 
SDS and after fixation with formaldehyde. GFP fluorescence is irreversibly destroyed by 
1% H2O2 and sulfhydryl reagents such as 1 mM DTNB (5,5´-dithio-bis-[2-nitrobenzoic 
acid]) (Inouye and Tsuji, 1994). Higher temperatures than 68°C cause denaturation of the 
protein with 50% of fluorescence lost at 78°C (Ward, 1982). 
 
EGFP is acidic with a monomer molecular weight of 27 kDa. EGFP is expressed as 
monomer soluble in aqueous solution. It exhibits pH stability in the range between pH 7.0 
and pH 11.5, the protein is 50% quenched at pH 5.5 (Patterson et al., 1997). EGFP is very 
resistant to photobleaching, perhaps because the fluorophore is so well shielded from 
chemical reactants, such as O2, in the ß-can (Tsien, 1998). To protect GFPs from 
bleaching, cell-permeant antioxidants, such as vitamin E analogues, can be used. In vivo 
the protein has an estimated half life of >24 hours (Li et al., 1998), whereas in fixed cells, 
fluorescence can still be detected after three months when slides are kept in the dark at 
4°C. EGFP can undergo photoconversion to a red fluorescent species under rigorously 
anaerobic conditions. The nature of this species emitting at 600 nm remaines to be 
clarified (Elowitz et al., 1997).  
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2.3.4 Application of GFPs as reporter gene 
 
GFPs can be utilized either as fusion partners or as active indicators. The most successful 
and numerous class of GFP application has been as partner in gene fusion constructs to 
monitor host protein localization and fate. The gene encoding GFP is fused with the gene 
encoding the endogenous protein of interest and the resulting chimera is to be expressed 
in the same function and localization as the endogenous protein. GFP has been targeted 
successfully to numerous proteins in practically every major organelle of the cell (Tsien, 
1998). A promoterless GFP gene can also be tagged to a heterologous promoter. EGFP 
expression level and pattern in the host organism thus describes promoter activity and 
specificity. As active indicator, GFP is less popular. The rigid protein shell protects the 
chromophore and hinders environmental sensitivity. The engineered fusion of GFP with 
the Shaker potassium channel is the first genetically encoded optical sensor of membrane 
potential (Siegel and Isacoff, 1997). Depolarization causes at most a 5% decrease in 
fluorescence in a time of approximately 85 ms. A more general way to make 
biochemically sensitive GFPs is to exploit fluorescence resonance energy transfer 
(FRET) between fluorescent proteins of different colors. This quantum mechanical 
phenomenon occurs when two fluorophores are in molecular proximity and the emission 
spectrum of one fluorophore (donor) excites the other fluorophore (acceptor). Any 
biochemical process changing the distance or orientation of the fluorophores modulates 
the efficiency of FRET (Tsien, 1993). GFP mutants with altered excitation and emission 
maxima are commercially available: enhanced blue fluorescent protein (EBFP), enhanced 
yellow fluorescent protein (EYFP), enhanced cyan fluorescent protein (ECFP) and red 
fluorescent protein (RFP) (CLONTECH, Palo Alto, CA). 
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2.3.5 Applications of EGFP in different species 
 
GFP fluorescence is species-independent. One of the first proposed applications of GFP 
was to detect gene expression in vivo in the nematode Caenorhabditis elegans, whose 
cuticle hinders access of substrates required for detection of other reporter genes (Chalfie 
et al., 1994). Since then, GFP has been expressed successfully in microbes, vertebrates, 
invertebrates, plants and various cell lines. Since the discovery of the EGFPmut1 by 
Cormack et al. (1996), and the availability of the EGFP vector at Clontech (Palo Alto, 
CA), EGFP is employed in a universal manner in genetic engineering. In Table 2, some 
current examples illustrate the broad field of EGFP applications. 
 
Table 2: Selection of current applications of EGFP 
Organism  Reference 
Escherichia coli                    (gram – bacterium) Cormack et al., 1996 
Aspergillus oryzae                 (funghi) Maruyama et al., 2001 
Drosophila melanogaster (insect) Sano and Nakamura, 2002 
Anopheles albimanus             (insect) Perera et al., 2002 
Zebrafish (fish) Krovel et al., 2002 
Transgenic mice (mammals) Okabe et al., 1997 
Transgenic pigs (mammals) Cabot et al., 2001 
Transgenic cattle  (mammals) Funahashi et al., 2001 
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2.3.5 Sensitivity of GFP and EGFP as reporter gene 
 
The sensitivity of GFP as reporter gene was described in a recent review as “somewhat 
disappointing” (Tsien, 1998). GFP´s independence from enzymatic substrates is on the 
one hand particularly useful for examination of intact organisms (Chalfie, 1994), but on 
the other hand allows no amplification of signals. A GFP molecule is not an enzyme that 
catalytically processes an indefinite number of substrates to form detectable 
chromophores: one GFP molecule containes at most one chromophore. As the ultimate 
sensitivity limit is set by cellular autofluorescence: at least 1 µM well folded GFP 
molecules are required in a mammalian cell to double fluorescence above background 
(Niswender et al., 1995). Mutant GFPs with higher extinction coefficients, like 
Clontech´s EGFP, improve this detection limit: 30 nM EGFP, which equals 4,000 
molecules per cell, are detectable in the cell cytoplasm. When expressed on the cell 
surface, 700 molecules are sufficient for detection (CLONTECHniques, 1997). When 
targeted to a defined subcompartment of the cell and analyzed by fluorescence 
microscopy, the number of EGFP molecules required can be reduced further: 300-3,000 
GFPs packed into a centrosome are readily visible as green dot inside a cell (Shelby et al., 
1996). This estimate already assumes perfect GFP maturation.  
 
Obviously the stronger the promoter/enhancers driving this transcription, the more 
protein will be detectable per cell. Most published reports of GFP or EGFP expression 
have used strong constitutive promoters from viruses such as the cytomegalovirus 
(CMV), SV40 or HIV long terminal repeats, or strong exogenous regulators such as the 
tetracycline transactivator system (Anderson et al., 1996; Gervaix et al., 1997; Okabe et 
al., 1997). 
 
 
 
 
 
 
Review of the literature 24
2.3.5 Sensitivity of GFP and EGFP as reporter gene 
 
The sensitivity of GFP as reporter gene was described in a recent review as “somewhat 
disappointing” (Tsien, 1998). GFP´s independence from enzymatic substrates is on the 
one hand particularly useful for examination of intact organisms (Chalfie, 1994), but on 
the other hand allows no amplification of signals. A GFP molecule is not an enzyme that 
catalytically processes an indefinite number of substrates to form detectable 
chromophores: one GFP molecule containes at most one chromophore. As the ultimate 
sensitivity limit is set by cellular autofluorescence: at least 1 µM well folded GFP 
molecules are required in a mammalian cell to double fluorescence above background 
(Niswender et al., 1995). Mutant GFPs with higher extinction coefficients, like 
Clontech´s EGFP, improve this detection limit: 30 nM EGFP, which equals 4,000 
molecules per cell, are detectable in the cell cytoplasm. When expressed on the cell 
surface, 700 molecules are sufficient for detection (CLONTECHniques, 1997). When 
targeted to a defined subcompartment of the cell and analyzed by fluorescence 
microscopy, the number of EGFP molecules required can be reduced further: 300-3,000 
GFPs packed into a centrosome are readily visible as green dot inside a cell (Shelby et al., 
1996). This estimate already assumes perfect GFP maturation.  
 
Obviously the stronger the promoter/enhancers driving this transcription, the more 
protein will be detectable per cell. Most published reports of GFP or EGFP expression 
have used strong constitutive promoters from viruses such as the cytomegalovirus 
(CMV), SV40 or HIV long terminal repeats, or strong exogenous regulators such as the 
tetracycline transactivator system (Anderson et al., 1996; Gervaix et al., 1997; Okabe et 
al., 1997). 
 
 
 
 
 
 
Review of the literature 25
2.3.6 Qualitative and quantitative analysis of GFP and EGFP expression in transgenic 
mice 
 
The first GFP transgenic mouse was generated by Ikawa et al. (1995). They announced 
fast, simple and non-invasive analysis of CMV-GFP integration and expression by 
observation of tails or fingers of newborn pups under a fluorescent lamp. Since then, 
numerous approaches have been made to examine integration and expression of GFPs in 
mouse tissue. While DNA integration can be routinely investigated by PCR (Table 3) and 
Southern blot, examination of protein expression has to cope with two delicate issues at a 
time:  
i) precise localization of expression  
ii) exact quantification of expression. 
In the following, different techniques of detection and quantification of GFP and EGFP in 
transgenic mouse tissue are displayed. 
 
Table 3: After extraction and purification of genomic DNA from mouse tissue 
according to laboratory manuals (Sambrok and Russel, 2001), EGFP 
(CVU55761) transgenic mice can be identified performing PCR. 
 
Primer sequence: sense (s) and antisense (as) Annealing 
conditions 
Reference 
5´-TCGAGCTGGACGGCGACGTAAA-´3 (s) 
5´-TAGTGGTTGTCGGGCAGCAGCA-´3 (as) 
 - Nolte et al., 2001 
5´-ACCCCGACCACATGAAGCAGC-´3 (s) 
5´-CGTTGGGGTCTTTGCTCAGGG-´3 (as) 
22 sec 55 °C / 
30 cycles 
Kaneko et al., 2001 
5´-TGACCTACGGCGTGCAGTGC-´3 (s) 
5´-TCACCTTGATGCCGTTCTTCT-´3 (as) 
- Pfeifer et al., 2002 
5´-ACGGCAAGCTGACCCTGAA-´3 (s) 
5´-GGGTGCTCAGGTAGTGGTT-´3 (as) 
60 sec 60°C / 
45 cycles 
Kato et al., 1999 
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Fluorescence microscopical analysis is an appropriate mean to exactly refer GFP 
expression to a specific cell type or cell organelle. Autofluorescence represents the main 
problem in fluorescence microscopy: many cell types or organs (kidney, hair follicles) 
display autofluorescence likely due to flavin coenzymes or mitochondria-bound NADH 
(Aubin, 1979; Lohmann, 1989). The use of the appropriate filter sets (common FITC 
filter sets for detection of EGFP) reduces autofluorescence, but improvement is limited. 
Tissue fixation techniques also play an important role.  
 
Ikawa et al. (1995) simply squeezed a piece of tissue under a coverglass or prepared 10 
µm thick cryosections. The freezing procedure turned out to increase background in 
fluorescence microscopy. Lathi et al. (2001) fixed testis tissue for 2 hours in 4% 
paraformaldehyde at room temperature (RT) and cut 70 µm thick sections on a 
vibratome. The sections were mounted with PBS and evaluated under the microscope. A 
broad organ spectrum was prepared for fluorescence microscopy by Kondoh et al. (1999). 
Mice were deeply anesthetized with phenobarbital and fixed by perfusion with 4% (w/v) 
paraformaldehyde-PBS via the left ventricle of the heart. Excised tissues were fixed again 
in 4% paraformaldehyde-PBS overnight at 4°C and then incubated in 20% sucrose-PBS 
for 48 h at 4°C. Pieces were then embedded in Tissue-Tek O.C.T. compound (Sacura 
Finetek, Torrance, CA), quickly frozen on dry ice and sectioned on a cryostat to 5-10 µm 
thickness. Although paraffin-embedded sections are reported to increase background 
fluorescence (Ikawa et al., 1999) and GFP is unlikely to withstand the complete 
dehydration required for paraffin or plastic embedding (Living Colors User Manual, 
2001), Walter et al. (2000) published the detection of EGFP in 5 µm thick paraffin 
sections. The method was established in CMV-EGFP transgenic mice. It includes a 
comparison between native preparations, propidium iodide and immunohistochemical 
stainings (ANIMALS, MATERIALS AND METHODS, chapter 3.6.2). Transgenic 
mouse embryos expressing EGFP can also be selected by fluorescence microscopy (Kato 
et al., 1999). After DNA microinjection, embryos were cultured in vitro to morula- or 
blastocyst-stage. In a microdrop of M2 medium, fluorescence could easily be observed 
under the microscope. 
 
Review of the literature 26
Fluorescence microscopical analysis is an appropriate mean to exactly refer GFP 
expression to a specific cell type or cell organelle. Autofluorescence represents the main 
problem in fluorescence microscopy: many cell types or organs (kidney, hair follicles) 
display autofluorescence likely due to flavin coenzymes or mitochondria-bound NADH 
(Aubin, 1979; Lohmann, 1989). The use of the appropriate filter sets (common FITC 
filter sets for detection of EGFP) reduces autofluorescence, but improvement is limited. 
Tissue fixation techniques also play an important role.  
 
Ikawa et al. (1995) simply squeezed a piece of tissue under a coverglass or prepared 10 
µm thick cryosections. The freezing procedure turned out to increase background in 
fluorescence microscopy. Lathi et al. (2001) fixed testis tissue for 2 hours in 4% 
paraformaldehyde at room temperature (RT) and cut 70 µm thick sections on a 
vibratome. The sections were mounted with PBS and evaluated under the microscope. A 
broad organ spectrum was prepared for fluorescence microscopy by Kondoh et al. (1999). 
Mice were deeply anesthetized with phenobarbital and fixed by perfusion with 4% (w/v) 
paraformaldehyde-PBS via the left ventricle of the heart. Excised tissues were fixed again 
in 4% paraformaldehyde-PBS overnight at 4°C and then incubated in 20% sucrose-PBS 
for 48 h at 4°C. Pieces were then embedded in Tissue-Tek O.C.T. compound (Sacura 
Finetek, Torrance, CA), quickly frozen on dry ice and sectioned on a cryostat to 5-10 µm 
thickness. Although paraffin-embedded sections are reported to increase background 
fluorescence (Ikawa et al., 1999) and GFP is unlikely to withstand the complete 
dehydration required for paraffin or plastic embedding (Living Colors User Manual, 
2001), Walter et al. (2000) published the detection of EGFP in 5 µm thick paraffin 
sections. The method was established in CMV-EGFP transgenic mice. It includes a 
comparison between native preparations, propidium iodide and immunohistochemical 
stainings (ANIMALS, MATERIALS AND METHODS, chapter 3.6.2). Transgenic 
mouse embryos expressing EGFP can also be selected by fluorescence microscopy (Kato 
et al., 1999). After DNA microinjection, embryos were cultured in vitro to morula- or 
blastocyst-stage. In a microdrop of M2 medium, fluorescence could easily be observed 
under the microscope. 
 
Review of the literature 27
Whole-body optical imaging of green fluorescent protein can be a non-invasive approach 
to localize protein expression (Yang et al., 1999). Intact transgenic mice are exposed to a 
470 nm UV lamp and the emitted fluorescence is collected through an external long pass 
filter. GFP fluorescence shines through structures like the flank or the skalp (Yang et al., 
1999). The technique also offers the possibility to visualize GFP expressing organs in 
opened body cavities of anesthetized mice (Pfeifer et al., 2001).  
 
The first quantification of GFP expression was achieved by fluorometry. Ikawa et al. 
(1995) homogenized tissue of different organs in PBS. After centrifugation of the 
homogenates, fluorescence was measured in the supernatants using a fluorometer. Protein 
concentrations in the supernatants were measured as well using a standard protein assay. 
Fluorescence at 509 nm was specified as fluorescence/(mg protein/ml). Recombinant 
GFP as standard for measurements is commercially available 
(http://www.turnerdesigns.com/). 
 
Because the excitation optimum for EGFP is close to 488 nm, EGFP expressing cells are 
suitable for fluorescence-activated cell sorting (FACS). A method to isolate individual 
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A semiquantitative method for protein detection is Western blotting (Sambrok and 
Russell, 2001). In the Living Colors User Manual (2001) SDS-PAGE is recommended 
with a 10% separation gel and 25-75 µg of lysate protein per lane on a minigel apparatus. 
Antibodies are commercially available from CLONTECH and Molecular Probes. 
Immunoprecipitation and subsequent SDS-PAGE of EGFP has been described for cells 
(Miserey-Lenkei et al., 2001). 
 
Table 4: Selected methods to analyze EGFP transgenic mice 
 
Analysis Method Literature 
EGFP gene copy number/ cell 
 
Multiplex real time PCR Klein et al., 2000 
EGFP expression pattern Whole body imaging, 
Western Blot 
 
Yang et al., 1999 ; 
Living ColorsUser Manual, 2001.
EGFP expression level 
 
Fluorometry, 
Western Blot 
 
Ikawa et al., 1995; 
Living ColorsUser Manual, 2001.
EGFP expressing cells/tissues 
 
FACS analysis Hadjantonakis and Nagy, 2000 
EGFP expressing cell type Histology Kondoh et al., 1999; 
Walter et al., 2000. 
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2.4 The use of Firefly Luciferase as reporter gene in transgenic mice 
 
2.4.1 Structure and characteristics of firefly luciferase 
 
The enzyme firefly luciferase was isolated form the North American Firefly by deLuca 
and McElroy (1978). The monomeric 61 kDa protein (Wood et al., 1985) catalyzes 
luciferin oxidation using ATP●Mg2+ as a cosubstrate (Figure 6). 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Bioluminescent reaction catalyzed by firefly luciferase 
 
The reaction emits yellow-green light for approx. 60 sec at pH 7.5 to 8.5 with the peak 
emission at 560 nm. The light intensity can be measured using a luciferase assay: less 
than 10-20 moles of luciferase have been detected under optimal conditions. The 
nucleotide sequence was determined from the analysis of firefly cDNA and genomic 
clones (de Wet et al., 1985; de Wet et al., 1987). The gene containes 6 introns. The 
complete cDNA sequence (2,387 bp) is deposited at GenBank accession number 
M15077. Luciferase was first expressed in mammalian cells in 1987 (de Wet et al., 
1987). The authors found luciferase to be a highly sensitive mean to monitor promoter 
activity. In addition Luciferin showed to diffuse across mammalian cytoplasmatic 
membranes, which allowed the detection of luciferase in intact cells. The vector utilized 
in this study, pB-Luciferase (pBL), contains the Photinus pyralis luciferase cDNA, fused 
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to the SV 40 poly (A) signal derived from pBLCAT (Luckow and Schütz, 1987) and 
cloned into the polylinker of Bluescript KSM13+ (Stratagene, Heidelberg, Germany) 
(Hoppe-Seyler et al., 1991). 
 
2.4.2 Qualitative and quantitative analysis of firefly luciferase in transgenic mice 
 
The first firefly luciferase transgenic mouse was created by Shockett et al. (1995). Since 
then, numerous approaches have been made to examine integration and expression of 
luciferase in mouse tissue. DNA integration can routinely be investigated using PCR and 
Southern blot. 
 
Wu et al. (2002) screened mouse genomic DNA, isolated according to laboratory 
manuals (Sambrok and Russel, 2001), for luciferase transgenesis, utilizing 5´-
GCAGATCTCAGAATACACTCAGA-´3 sense and 5´-ATAAATAACGCGCCCAAC 
AC-3` antisense primers to amplify a sequence from the luciferase gene (pGL3, 
Promega) in 30 cycles at 55°C annealing temperature. Southern blot can be performed for 
quantification of transgene copy number (Chen et al., 1996; Kistner et al., 1996). As 
standards for the determination of copy numbers, as well as for positive control, 10 µg of 
genomic DNA from a wildtype mouse spiked with an appropriate amount of linearized 
plasmid were used. Northern blot analysis is described in detail by Wu et al. (2002). 
 
Expression of luciferase protein in different organs can exactly be quantified by 
Luciferase assay systems (Promega, Madison, Wi). Mouse tissue has to be processed 
prior to subjecting it to luciferase assay. An overview of selected methods is given on 
Table 5. The protein content of the tissue extract has to be measured by protein assays 
(e.g. Pierce, Rockford, IL). Luciferase activity is specified as relative light units (RLU) 
per mg protein in a specific time (10 sec) after subtraction of the lysis buffer background. 
Luciferase activity in non-transgenic organs ranges from 0 (heart) to 617 (lymphnodes). 
Firefly luciferase protein standard (Promega, Madison, Wi) can be added to extracts of 
wildtype mouse tissue as positive control (Shockett et al., 1995). 
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Localization of luciferase protein expression can not only be obtained by assay, 
immunoprecipitation or Western blot analysis of organs (Shockett et al., 1995; Swoap, 
1998), but also by histological methods and imaging of bioluminescence in living 
animals (Wu et al., 2002). 
 
Imaging of bioluminescence in living animals was achieved in MMP-13-luciferase 
transgenic mice. The MMP-13 gene is known to play a role in cutaneous wound healing. 
Anesthetized wounded mice were imaged as follows: luciferin/DMSO solution was 
applied topically onto wounds and unwounded skin. After 5 minutes animals were placed 
in a light-tight chamber. A gray-scale image and a pseudocolor image were taken using a 
intensified charged coupled device (ICCD) camera. Pictures were superimposed by 
image processing software. Background values from unwounded skin were subtracted 
from wound signals (Wu et al., 2002). This method of monitoring biolumeniscence can 
also be applied to other mouse organs in vivo. Luciferin can be administered systemically 
(126 mg/kg body weight) in mice and rats (Honigman et al., 2001). Luminescence is 
measured between 5 and 20 min after injection of luciferin, depending on the target 
organ. In vitro imaging of bioluminescence in 440 µm thick tissue slices was reported by 
Geusz et al. (1997). 
 
In situ hybridization analysis of mouse skin can be achieved by digoxigenin-labeled 
riboprobes as described by Hoff et al. (1999). Mouse skin was fixed in 4% 
paraformaldehyde, embedded in paraffin, deparaffinized with xylenes and rehydrated to 
PBS. Tissue was fixed in paraformaldehyde before and after treatment with proteinase K. 
Following acetylation with 0.5% acetic anhydride, tissue was dehydrated through graded 
ethanols and air-dried prior to hybridisation. Tissue sections were hybridized at 55°C 
with digoxigenin-labeled riboprobes (antisense and sense) in a humid chamber. After 
washing of the slides, the digoxigenin detection procedure was carried out using the 
genius TM3kit (Boehringer, Mannheim, Germany). 
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Detection of luciferase protein by immunohistochemistry has so far only been described 
for rat muscle tissue (Ashley and Russell, 2000). Cryosections (10 µm thick) were fixed 
with 4% paraformaldehyde and incubated with the primary anti-luciferase antibody 
(Promega, Madison, WI) and a secondary, fluorescein-labeled antibody. The sections 
were analyzed for luciferase protein expression under the microscope.
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3 ANIMALS, MATERIALS AND METHODS 
 
3.1  Animals 
 
3.1.1 Mice 
 
Female NMRI outbred mice at the age of 8 weeks to 6 months were chosen as recipient 
animals. Vasectomized NMRI males were kept for synchronisation of the recipients. 
B6D2F1 hybrid mice (C57BL/6 female x DBA/2 male) were utilized for production of 
fertilized oocytes. Transgenic founders were backcrossed to C57BL/6 inbred strain 
background. Mice were purchased at Charles River Laboratories (Sulzfeld, Germany). 
 
3.1.2 Housing and husbandry 
 
Mice were maintained in the facilities of the Gene Center under non-barrier conditions 
(Table 6). Acidified water (6 mM HCl) was provided ad libitum in bottles. Pregnant mice 
recieved breeding diet (Ssniff®M-Z extruded pellets) ad libitum. Maintenance diet 
(Ssniff®R/M-H pellets) was fed ad libitum to the others. Fodder pellets, as well as any 
other solid objects entering the mouse facility, were autoclaved. Mice were kept, 
separated by sex, in standard macrolon cages with grid lids on softwood fibre, paper and 
hay. Enrichment was provided in all cages of sufficient size with aspen wood pieces and 
activity wheels. 
 
Table 6: Environmental conditions in the mouse facility 
Parameter Description 
Type of facility Conventional facility (non-barrier) 
Temperature 21°C (+/- 1°C) 
Relative humidity 60 % (+/- 5%) 
Ventilation rate 15 air changes/hour 
Air pressure 2 pascal positive pressure 
Lighting regimen 12 hours light/12 hours dark 
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3.1.3 Breeding system 
 
Founders obtained from DNA-microinjection were bred from the age of 8 weeks to 6 
months (females) or up to 12 months (males) with C57BL/6 inbred mice to generate 
transgenic lines. Female and male mice were caged together until the appearance of a 
vaginal plug. Males were thereafter caged singly. 
 
3.2 Preparation of constructs for DNA-microinjection 
 
The plasmids pBL-HERV-L and pEGFP-HERV-H-H6 were kindly donated by Dr. 
Schoen and PD Dr. Leib-Mösch, GSF, Neuherberg. Transformed plasmids were 
propagated using competent bacteria. Plasmid DNA was isolated in minipreps. The gene 
construct was released from the vector backbone by restriction enzyme digest and eluted 
in injection buffer. 
 
3.2.1 The pBL-HERV-L construct 
 
Figure 7: Schematic representation of gene construct pBL-HERV-L (3,123 bp). 
HERV-L LTR: Human Endogenous Retrovirus Long Terminal Repeat from family L 
(430 bp); CACACCC: characteristic motive of the keratinocyte-specific EBV ED-L2 
promoter and other keratinocyte-specific promoters. Two of them have been identified in 
the HERV-L LTR (Leib-Mösch, 2000); AP: AP1 is a characteristic motive for the 
keratinocyte specific expression of the human profiaggrin gene (Maurer et al., 1991); 
TATA-box: element of eukaryotic and yeast promoters; pBL: expression vector cloned 
by Hoppe-Seyler et al. (1991); luciferase: P. pyralis luciferase complementary 
deoxyribonucleic acid (1714 bp); poly A: SV 40 polyadenylation signal (979 bp). 
 
 
pBL
luciferaseCACACCC TATA poly A
HERV-L  LTR
Bam HI Xho IDde IHind III
APAP
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3.2.2 The pEGFP-HERV-H-H6 construct 
 
 
 
 
Figure 8:      Schematic representation of gene construct pEGFP-HERV-H-H6 (1,455 bp). 
HERV-H-H6 LTR: Human Endogenous Retroviral Long Terminal Repeat from family H 
(438 bp); Type 1: type one repeat; Type 2: type two repeat; TGTTCT: steroid-regulatory 
sequence (Kasumata et al., 1998); TATA-box: element of eukaryotic and yeast 
promoters; GC: GC-rich region containing binding sites for transcription factors Sp1 and 
Sp 3, which may be involved in the specific expression pattern of HERV-H elements 
(Nelson et al., 1996; Sjottem et al.,1996); EGFP: coding region for the Enhanced Green 
Fluorescent Protein (784 bp); poly A: SV 40 polyadenylation signal (233 bp). 
 
3.2.3 Preparation of competent bacteria 
 
E. coli bacteria strain TOP 10 were grown in 300 ml Luria-Bertani Medium (LB) at  
37°C with vigorous shaking to an OD 600 of 0,7 to 0,8. After chilling on ice, bacteria were 
recovered by centrifugation at 4,000 rpm (rounds per minute) and 4°C for 10 minutes 
(min) in a centrifuge (Sorval, RC5C Plus) using the SS-34 rotor. 
 
LB medium: Bacto-tryptone 10 g 
  Bacto-yeast extract 5 g 
  NaCl   10 g 
  Bidistilled water ad 1 l 
The solution was adjusted to pH 7.0 with 5 M NaOH and autoclaved. 
 
After removal of the medium, the pellet was carefully resuspended in 225 ml of ice-cold 
Tfb I buffer and stored for 10 min on ice. Bacteria were centrifuged and the supernatant 
was removed. As from now, centrifugation was carried out in an Eppendorf centrifuge 
(5417 R) using the F 45-30-11 rotor. 
EGFPTATA poly A
HERV-H-H6 LTR pEGFP
Xho I Afl IIXba IEco RI
GCType 2Type 1 TGTTCT
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Tfb I buffer:  1 M KOAc  9 ml 
   3 M MnCl2  5 ml 
   1 M CaCl2  30 ml 
   Glycerol  45 ml 
   Bidistilled water 211 ml 
MnCl2 was sterilized by filtration and added to the autoclaved components. 
 
The pellet was resuspended in 9 ml ice-cold Tfb II buffer. Competent bacteria were 
aliquoted (200 µl) in microfuge tubes and stored at –80°C. 
 
Tfb II buffer:               1 M MOPS  0.3 ml 
   1 M KCl  3 ml 
   1 M CaCl2  3.2 ml 
   Glycerol   4.5 ml 
   Bidistilled water 19 ml 
 
3.2.4 Transformation of bacteria 
 
Competent bacteria were thawed on ice. A volume of 40 µl was transferred to a sterile 
centrifuge tube and 1 µl of plasmid (10 ng/µl) was added. The tubes were stored on ice 
for 30 min, followed by 30 s incubation at 37°C. The tubes were rapidly returned to ice, 
allowing the cells to chill for 5 min. 800 µl of SOC medium were added to each tube and 
cultures were incubated for 1 hour (h) at 37°C with vigorous shaking. 
 
SOC medium:  Bacto-tryptone peptone  20 g 
   Bacto-yeast extract   5 g 
   NaCl     0.5 g 
   Bidistilled water   up to 950 ml 
10 ml of a 0.25 M KCl solution were added. The pH was adjusted to 7.0 and the solution 
was autoclaved. Finally 100 mM MgCl2 and 20 mM glucose were added. 
 
The appropriate volume of transformed competent cells was transferred onto four 
agarose-LB plates with the corresponding antibiotic (Table 7). Using a sterile glass rod, 
the transformed cells were gently spread over the surface of the agar plate. Plates were 
inverted and incubated at 37°C. Colonies appeared within 16 h. 
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Agarose LB:  LB medium  1 l 
   Agar, granulated 15 g 
After autoclaving, the solution was swirled gently to distribute the melted agar evenly. 
When the temperature reached 50°C, the antibiotic was added and 35 ml medium were 
poured directly from the flask in 90 mm Petri dishes. After the medium had hardened 
completely, plates were inverted and stored at 4°C. 
 
Table 7:  Different quantities of competent cells were applied to the agar plates. 
After incubation at 37°C, single bacteria colonies were picked.   
Plate  Plasmid Antibiotic Volume of competent cells 
A pBL-HERV-L Ampicillin 100 µg/ml 5 µl 
B pBL-HERV-L Ampicillin 100 µg/ml 50 µl 
C pEGFP-HERV-H-H6 Kanamycin 30 µg/ml 5 µl 
D pEGFP-HERV-H-H6 Kanamycin 30 µg/ml 50 µl 
 
 
3.2.5 Preparation of plasmid DNA (Miniprep) 
 
Plasmid DNA was isolated from E. coli using the QIA prep Spin Miniprep Kit® 
(Quiagen, Hilden, Germany) according to the manufacturer´s instructions. Colonies were 
picked with a sterile tooth-pick, immersed in 4 ml LB medium with the appropriate 
antibiotic (100 µg/ml Ampicillin or 30 µg/ml Kanamycin) and incubated for 12 h at 37°C 
with vigorous shaking. 2 ml of the bacterial culture were transferred to a centrifuge tube 
and centrifuged at 13,000 rpm for 30 s at 4°C. The supernatant was discarded and the 
bacterial pellet resuspended in 250 µl P1 buffer. Tubes were placed on ice. 
 
P1 buffer:   Tris/HCl pH 8,5 50 mM 
   EDTA   10 mM 
   RNase A  100 µg /ml 
 
250 µl of buffer P2 were added and the tube was inverted gently 6 times to mix. 
 
P2 buffer:  NaOH   200 mM 
   SDS   1 % (w/v) 
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350 µl of buffer N3 was added and the tubes were again inverted gently 6 times. 
 
N3 buffer:  contains potassium acetate and a chaotrope salt 
    
Tubes were centrifuged for 10 min, at 4°C and 13,000 rpm. The supernatants were 
decanted to the provided spin columns. Columns were centrifuged 60 s at 13,000 rpm and 
the flow-through was discarded. Columns were washed by adding 750 µl of buffer PE 
and centrifugation (13,000 rpm) for 60 s. 
 
PE buffer:   80 % Ethanol 
 
After removal of the flowthrough, the columns were centrifuged for an additional min to 
remove residual wash buffer. The columns were placed into new 1.5 ml microfuge tubes. 
DNA was eluted after application of 50 µl TE buffer (10 mM Tris-HCl; pH 8) to the 
center of the column, incubation for 2 min at RT and centrifugation (13,000 rpm) for 1 
min. 
 
3.2.6 Restriction enzyme digestion  
 
Restriction enzyme digests from plasmid DNA were performed to release the gene 
constructs from the vector backbone for microinjection (Table 8). All buffers and 
enzymes except for 10x buffer H and Sca I (Roche, Mannheim, Germany) were 
purchased from MBI fermentas, St Leon-Rot, Germany. 
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Table 8: Conditions for restriction enzyme digestion 
pBL-HERV-L 
20 µl plasmid DNA 400 ng/µl 
112 µl H2O  
16 µl 10x buffer H  50 mM Tris-HCl; 10 mM MgCl2; 100 mM NaCl; 1 mM DTE. 
4 µl Sca I  10 U/µl 
4 µl Not I  10 U/µl 
4 µl Xho I  10 U/µl 
 
pEGFP-HERV-H-H6 
20 µl plasmid DNA 400 ng/µl 
96 µl H2O  
32 µl
  
2x buffer Y+/ 
Tango 10x 
33 mM Tris-acetate pH 8.5 at 37°C ; 10 mM Mg-acetate ;  
66 mM potassium acetate ; 0,1 mg/ml BSA. 
4 µl Bsp TI (Afl II) 10 U/µl 
4 µl Xho I 10 U/µl 
 
Both digests were performed in an incubator at 37°C over night. 32 µl 6x loading dye 
(0.09% bromophenol blue, 0.09% xylene cyanol FF, 60% glycerol, 60 mM EDTA) was 
added to each sample. Two 1% TAE agarose gels were prepared. 
 
50 x TAE pH 8.5:  Tris   242 g/l 
                                     glacial acetic acid 5.71% (v/v) 
                                     Na2 EDTA-dihydrate 37.2 g/l 
 
Each construct was distributed into 4 slots of one gel. Plasmid DNA fragments were 
separated by electrophoresis. One half of each gel, containing the DNA length standard 
and one plasmid slot, was dyed in an ethidiumbromide bath (0.5 µg EtBr/ml TAE) for 45 
min at RT. The DNA fragment of the appropriate size was detected by ultraviolet 
illumination and marked by incision. Stained and unstained parts of the gel were 
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thereafter put together and gel slices were cut out of the unstained half using the gel 
incision as mark.  
 
3.2.7 Extraction of DNA fragments from agarose gels 
 
The DNA was extracted from the gel slices using the Jetquick Spin Column Technique® 
(Genomed, Bad Oeyenhausen, Germany) according to the manufacturer´s instructions. 
Agarose gel slices were weighed and distributed into microfuge tubes. For each 100 mg 
gel slice 300 µl of solution L1 (contains concentrated NaClO4, sodium acetate and TBE-
solubilizer) was added. After 20 min incubation at 50°C, the samples were loaded into 
the provided spin column. Centrifugation was carried out at RT and 14,000 rpm for 1 
min. The flowthrough was discarded. Another 500 µl of solution L1 were added to the 
columns, incubated for 1 min and centrifuged at 14,000 rpm. The flowthrough was 
discarded and 500 µl of solution L2 (contains 80 % Ethanol, NaCl, EDTA and Tris/HCl) 
was loaded into the column. After 5 min of incubation, the columns were centrifuged at 
14,000 rpm for 1 min. The flowthrough was discarded and the centrifugation repeated. 
Jetquick Columns were placed into a new microfuge tube and 30 µl injection buffer (5 
mM Tris, 0.1 mM EDTA, pH 7.38) preheated to 70°C were added. After an incubation 
time of 1 min, centrifugation was carried out with 14,000 rpm for 1 min. The DNA 
concentration was determined using a spectrophotometer. As control 2 µl of the DNA 
solution were electrophoretically separated on a agarose gel and the concentration was 
estimated using the lambda DNA/EcoRI + Hind III marker as reference (MBI fermentas, 
St Leon-Rot, Germany). The eluted fragments for DNA microinjection were stored at  
–20°C.  
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3.3 Production of transgenic mice 
 
3.3.1 Superovulation and isolation of fertilized oocytes 
 
At noon of day one, B6D2F1 mice were injected intraperitoneally with 8 international 
units (U) PMSG (pregnant mares serum gonadotropin). At noon of day three, donor mice 
were injected intraperitoneally with 7 U HCG (human chorionic gonadotropin) and 
thereafter caged with stud males overnight. In the morning of day four, successful mating 
was checked by looking for the presence of vaginal plugs. Positive mice were sacrificed 
by cervical dislocation. Ovaries, oviduct and uterus were collected and embryos were 
flushed from the ampulla of the oviduct into M2 medium. 
 
M2_medium:  NaCl   94.66 mM 
KCl   4.78 mM 
   CaCl2.H2O  1.71 mM 
   KH2PO4  1.19 mM 
   MgSO4.7H2O  1.19 mM 
NaHCO3  4.15 mM 
HEPES   20.85 mM 
Sodium lactate  23.24 mM 
Sodium pyravate 0.33 mM 
Glucose  5.56 mM 
 
3.3.2 Microinjection 
 
On a depression slide in a flat drop of M2 medium overlayed with equilibrated paraffin 
oil, only fertilized and intact oocytes were selected under the microscope for injection of 
1-2 pl DNA solution (3-5 ng DNA/µl injection buffer). Injected oocytes were stored in 
M2 medium until transfer to recipients. 
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3.3.3 Transfer of embryos into the oviduct of synchronized recipients 
 
Transfer of injected embryos was performed on the same day into the oviducts of 
synchronized NMRI mice. Foster mothers had been mated with vasectomized NMRI 
males over night. A positive vaginal plug indicated successful synchronisation.  
 
Recipients were anesthetized with neuroleptanalgesia (ketamine hydrochloride 100 
mg/kg body weight + xylazine 10 mg/kg body weight). Through paravertrebral incisions 
in the lumbar region, the reproductive tract was exposed and embryos inserted into the 
infundibulum of the oviducts. Ovary, oviduct and ends of the uterus were put back in 
place. Incisions were clamped. To observe the development of pregnancy, recipient mice 
were weighed every second day. In case of weight loss they were dissected to check for 
signs of abortion. 
 
3.4 Identification of transgenic mice 
 
3.4.1 Identification using the Polymerase Chain Reaction (PCR) 
 
3.4.1.1 Preparation of genomic DNA from mouse tails 
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3.4.1.2 PCR conditions 
 
To confirm the integrity of the DNA, a sequence of the mouse ß-actin gene was 
amplified. For detection of transgenesis, a sequence of the corresponding reporter gene 
was amplified. PCR reactions with a total volume of 20 µl were prepared on ice, mixed 
and directly transferred to Biometra Uno II thermocyclers (Biometra, Göttingen, 
Germany). PCR reagents derived from Taq DNA polymerase® (Quiagen, Hilden, 
Germany). 
 
ß-Actin PCR 
reagents concentration volume (µl) 
reaction buffer 10 x 2 
dNTPs 1 mM 2 
primer sense  2 µM 2 
primer antisense  2 µM 2 
MgCl2   50 mM 1.25 
Q Solution (contains DMSO)  4 
H 2 O bidest.  3.7 
Taq polymerase  5 U/µl 0.1 
DNA templete  3  
 
ß-actin primer sense:  5`GGC ATC GTG ATG GAC TCC 3` 
ß-actin primer antisense. 5`GTC GGA AGG TGG ACA GGG 3` 
amplification steps temperature time 
1 denaturation 94°C 4 min 
2 denaturation 94°C 1 min 
3 annealing 60°C 1 min 
4 extension 72°C 2 min 
5 extension 72°C 10 min 
6 cooling 4°C ∝ 
 
Step 2 to 4 were repeated 30 times before progressing to step 5 and 6. 
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EGFP PCR 
reagents concentration volume (µl) 
reaction buffer 10 x 2 
dNTPs  1 mM 2 
primer sense         2 µM 1 
primer antisense   2 µM 1 
MgCl2   50 mM 1.25 
Q Solution (contains DMSO)  4 
H 2 O bidest.  5.7 
Taq polymerase  5 U/µl 0.1 
DNA Templete  3 
 
eGFP-primer sense:  5` TCG AGC TGG ACG GCG ACG TAA A 3` 
eGFP-primer antisense: 5` TAG TGG TTG TCG GGC AGC AGC A 3` 
 
amplification steps temperature time 
1 denaturation 94°C 4 min 
2 denaturation 94°C 1 min 
3 annealing 62°C 1 min 
4 extension 72°C 1 min 
5 extension 72°C 10 min 
6 cooling 4°C ∝ 
 
Step 2 to 4 were repeated 30 times before progressing to step 5 and 6. 
 
pBL PCR 
reagent concentration volume (µl) 
reaction buffer 10 x 2 
d NTPs  1 mM 2 
primer sense         2 µM 2 
primer antisense  2 µM 2 
MgCl2   50 mM 1.25 
Q Solution (contains DMSO)  4 
H 2 O bidest.  3.7 
Taq polymerase  5 U/µl 0.1 
DNA Templete  3 
 
luciferase primer sense:   5` CCG CTG GAG AGC AAC TGC AT 3` 
luciferase primer antisense:  5 `TCT ATG CGG AAG GGC CAC AC 3 ` 
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amplification steps temperature time 
1 denaturation 94°C 4 min 
2 denaturation 94°C 1 min 
3 annealing 60°C 1 min 
4 extension 72°C 2 min 
5 extension 72°C 10 min 
6 cooling 4°C ∝ 
 
Step 2 to 4 were repeated 30 times before progessing to step 5 and 6. 
 
3 µl bidistilled H2O as well as 3 µl Kawasaki buffer served as negative control in each 
PCR. 100 ng mouse genomic DNA served as positive control in each ß-actin PCR. As 
positive control for pBL-HERV-L and pEGFP-HERV-H-H6 PCRs 100 ng of the 
appropriate plasmid were utilized. 
 
3.4.1.3 Agarose gel electrophoresis 
 
After cycling, the PCR reactions were mixed with 6 x loading dye and separated on 2% 
TAE agarose gels containing 0.5 µg/ml ethidiumbromide. pUC Mix Marker 8 (MBI 
fermentas, St Leon-Rot, Germany) was employed as DNA length marker displaying a 
range from 67 bp to 1,116 bp.  
 
3.4.2 Southern blot analysis 
 
3.4.2.1 Extraction of genomic DNA and determination of concentration 
 
Genomic DNA was isolated from mouse tissue using the Wizard genomic DNA 
purification kit® (Promega, Wisconsin, USA) according to the manufacturer´s 
instructions. Pieces of mouse liver (3-5 mm2) were incubated for 16 h at 55°C with gentle 
shaking in 116 µl 0.5 M EDTA solution pH 8, 484 µl Nuclei Lysis solution and 17.5 µl 
of proteinase K solution (20 mg/ml). After confirming the complete digestion of samples, 
3 µl of RNase solution (4 mg/ml) were added. The mixtures were incubated for 15 min at 
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37°C. Samples were then cooled to RT, mixed with 200 µl Protein Precipitation solution 
and vortexed vigorously. After 5 min of incubation on ice and 4 min centrifugation at 
14,000 rpm, the supernatants were transferred to new tubes. 600 µl isopropanol (RT) 
were added. Mixtures were gently inverted until thread-like strands of DNA formed a 
visible mass. DNA pellets were recovered by centrifugation (14,000 rpm, 2 min), washed 
with 600 µl 70% ethanol, allowed to air-dry for 10 min and resuspended in 50 µl 
bidistilled water. To assure that the DNA was completely dissolved, it was stored at 4°C 
for at least 24 h prior to further manipulation. DNA concentration was determined by 
measuring the optical density (OD) of 100 µl of a 1:50 dilution of the samples at 260 nm 
and 280 nm in a spectrophotometer. DNA concentration was calculated using the 
following equation:  
 
DNA concentration (µg/ml) = dilution factor x OD260 x 50 (unit factor) 
 
DNA purity was assessed on behalf of the ratio OD260/OD280. Ratios between 1.8 and 2.0 
were considered to be appropriately pure. 
 
3.4.2.2 Digestion of genomic DNA 
 
Genomic DNA of pEGFP-HERV-H-H6 transgenic mice was seperately digested with 
Hind III and Eco R1 (MBI fermentas, St Leon-Rot, Germany) for 16 h at 37°C in an 
incubator. 
 
Hind III digest Eco R1 digest 
Hind III (50 U/µl) 2 µl Eco R1 (50 U/µl) 2 µl 
Buffer R + (10 x) 5 µl Buffer O + (10 x) 5 µl 
Genomic DNA x µl  (15 µg) Genomic DNA x µl  (15 µg) 
Bidistilled water ad 50 µl Bidistilled water ad 50 µl 
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Plasmid DNA of the pEGFP-HERV-H-H6 plasmid was digested for 2 h at 37°C. 
 
Hind III digest 
Hind III (0.2 U/µl) 1 µl 
Buffer R + (10 x) 1.5 µl 
Plasmid DNA (10 ng/µl) 1.5 µl 
Bidistilled water 11 µl 
 
10 µl of 6 x loading buffer were added to the genomic digests and 15 µl H2O plus 6 µl  
6x loading buffer was added to the plasmid digest. The cleaved DNA was separated on a 
0.8% TAE agarose gel in 4 h at 80 V (voltage constant). Gel as well as running buffer  
(1 x TAE) contained 8 µl EtBr/l. The gel was then photographed with a ruler, marked at 
the bottom right-hand corner and trimmed.  
 
3.4.2.3 Transfer of the DNA  
 
Depurination of the DNA in the gel was accomplished by soaking the gel in several 
volumes of 0.2 N HCl for 30 min. The gel was rinsed several times with deionized H2O. 
Thereafter, it was soaked in 10 gel volumes of denaturation solution for 45 at RT with 
gentle agitation. 
 
Denaturation solution:  NaCl  1.5M 
     NaOH  0.5M 
 
After rinsing the gel briefly in deionized H2O, the gel was soaked twice in neutralization 
buffer at RT (1 x 30 min, 1 x 15 min). 
 
Neutralization buffer:   Tris (pH 7.4) 1M 
     NaCl  1.5 M 
 
Meanwhile the membrane was prepared for transfer by soaking it 5 min in 10 x SSC.  
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10 x SSC:    87.65 g/l NaCl 
     44.1 g/l Sodium citrate 
The pH was adjusted to 7.0 with a few drops of 10 N NaOH solution before autoclaving. 
 
The DNA was transferred from the gel to a Biodyne® nylon membrane (Pall, NY, USA) 
by neutral blotting. 10 x SSC was used as neutral transfer buffer. The assembly of the 
transfer apparatus is displayed in Figure 9. Blotting papers, paper towels and the nylon 
membrane were cut to fit the gel size. Blotting papers were wetted and piled onto one 
another. At each layer, air bubbles were removed with the help of a glass pipette. 
Capillary transfer took place at RT for 36 h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Assembly of the Southern blot transfer apparatus 
 
After DNA transfer, the membrane was rinsed 5 min in 6 x SSC at RT and air-dried for 
30 min. To fix the DNA, the membrane was baked at 70°C for 1 h and thereafter exposed 
to UV light (0.12 Joule for 136.5 cm²) to crosslink nucleic acids. 
 
  weight ~ 400 g
glass plate 
glass plate 
paper 
towels 
3 x blotting 
paper 
3 x blotting paper
nylon membrane 
gel 
baking dish filled with neutral transfer buffer
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3.4.2.4 Radioactive probe labeling 
 
The probe (776 bp) was released by restriction enzyme digestion from the pEGFP-
HERV-H-H6 plasmid, separated on a 1% TAE agarose gel by electrophoresis and 
extracted using the Jetquick Spin Column® Technique as described in 3.2.7. 
 
Not I and Eco RI double digest 
DNA (2 µg/µl) 3 µl 
Not I (10 U/µl) 2 µl 
Eco RI (10 U/µl) 2 µl 
H2O 38 µl 
Buffer 0 + (10 x) 4 µl 
The digest was incubated at 37°C for 2 h. 
 
The probe was labeled with the Hexa label DNA labeling kit® (MBI fermentas, St Leon-
Rot, Germany) and α32P-dCTP as follows: 5 µl of DNA (20 ng/µl), 10 µl hexamers in 5 x 
buffer and 28 µl deionized H2O were boiled at 95°C for 10 min. The mixture was 
thereafter chilled on ice and the following reagents were added: 3 µl Mix C, 3 µl α32P-
dCTP and 1 µl Klenow polymerase (5 U/µl, exonuclease-). After incubation for 15 min at 
37°C, 4 µl dNTPs (0.25 mM) were added and the mixture was put back to 37°C for 
another 5 min. To stop the reaction, 1 µl of EDTA (0.5 M, pH 8.0) was added. 
Unicorporated nucleotides were removed by purification with Amersham Microspin 
columns type S-300 (Amersham Pharmacia, Freiburg, Germany) according to the 
manufacturer`s instructions. 5 µl of a 1:100 dilution in water were put into a scintillation 
vial and the number of counts per minute (cpm) were determined in a multi-purpose 
scintillation counter. The final cpm value was obtained employing a formula to correct 
the lack of scintillation fluid in the measurement:  
 
radioactivity/µl = cpm x 20 (dilution) x 1.55 
 
The probe was stored on ice to be used at the same day. 
Animals, Materials and Methods 51
3.4.2.4 Radioactive probe labeling 
 
The probe (776 bp) was released by restriction enzyme digestion from the pEGFP-
HERV-H-H6 plasmid, separated on a 1% TAE agarose gel by electrophoresis and 
extracted using the Jetquick Spin Column® Technique as described in 3.2.7. 
 
Not I and Eco RI double digest 
DNA (2 µg/µl) 3 µl 
Not I (10 U/µl) 2 µl 
Eco RI (10 U/µl) 2 µl 
H2O 38 µl 
Buffer 0 + (10 x) 4 µl 
The digest was incubated at 37°C for 2 h. 
 
The probe was labeled with the Hexa label DNA labeling kit® (MBI fermentas, St Leon-
Rot, Germany) and α32P-dCTP as follows: 5 µl of DNA (20 ng/µl), 10 µl hexamers in 5 x 
buffer and 28 µl deionized H2O were boiled at 95°C for 10 min. The mixture was 
thereafter chilled on ice and the following reagents were added: 3 µl Mix C, 3 µl α32P-
dCTP and 1 µl Klenow polymerase (5 U/µl, exonuclease-). After incubation for 15 min at 
37°C, 4 µl dNTPs (0.25 mM) were added and the mixture was put back to 37°C for 
another 5 min. To stop the reaction, 1 µl of EDTA (0.5 M, pH 8.0) was added. 
Unicorporated nucleotides were removed by purification with Amersham Microspin 
columns type S-300 (Amersham Pharmacia, Freiburg, Germany) according to the 
manufacturer`s instructions. 5 µl of a 1:100 dilution in water were put into a scintillation 
vial and the number of counts per minute (cpm) were determined in a multi-purpose 
scintillation counter. The final cpm value was obtained employing a formula to correct 
the lack of scintillation fluid in the measurement:  
 
radioactivity/µl = cpm x 20 (dilution) x 1.55 
 
The probe was stored on ice to be used at the same day. 
 Animals, Materials and Methods 52
3.4.2.5 Hybridization, washing and signal detection 
 
The crosslinked membrane was placed into a glass tube and prehybridized with 10 ml 
Rapid-Hyb buffer (Amersham Pharmacia, Freiburg, Germany) at 65°C for 2 h. 
Meanwhile the labeled probe was boiled for 10 min at 95°C, directly put back on ice and 
then added completely to the prehybridization reaction. The membrane was hybridized at 
65°C for 12 h. The following washing steps were performed to remove non-specificly 
bound probes from the membrane:   
 
• 20 min RT 2 x SSC, 0.1% SDS;  
• 15 min 65°C 1 x SSC, 0.1% SDS;  
• 15 min 65°C 0.1 x SSC, 0.5% SDS;  
• 20 min 42°C 0.4 M NaOH;  
• 30 min 42°C 0.1 x SSC, 0.1% SDS.   
 
Only the first three washes were put in the radioactive waste. The membrane was sealed 
in a plastic bag and exposed to a Storage Phosphor screen. The membrane was not 
allowed to dry at any time. 
 
3.5 Evaluation of gene expression at RNA level 
 
3.5.1 Reverse transcription PCR (RT-PCR) 
 
To avoid degradation by RNases, following rules were observed while working with 
ribonucleic acids: 
• gloves were worn all the time and changed frequently 
• all equipment was autoclaved 
• glassware, magnet stirrers and dissection instruments were baked at 180°C for at 
least 4 h 
• benches were cleaned with 100% ethanol 
• to all solutions, except those containing Tris, 0.1% DEPC (diethylpyrocarbonate) 
was added 
• all procedures were carried out on ice 
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3.5.1.1 Extraction of RNA from mouse tissue 
 
Tissue samples (10-100 mg) stored at –80°C were cut on blocks of dry ice and added 
frozen to 1 ml of TriPure® Isolation Reagent (Roche, Mannheim, Germany). 
 
TriPure® Isolation Reagent:   phenol    40% 
     guanidiniumthiocyanate 24% 
 
Homogenization was carried out immediately in a polytron blender at 26,000 rpm 
(position E for skin) or at 23,500 rpm (position D for muscle, heart, liver, kidney, 
mammary gland, lung, brain and gonads) for 1 min. After each homogenization step, the 
homogenizer was cleaned with bidistilled water and 0.2 M NaOH. Homogenates were 
stored on ice until further processing. Skin homogenate was liberated from hair by 
centrifugation and transfer of the supernatant to a new tube. RNA was isolated from the 
homogenates by extraction with chloroform, precipitation with isopropanol and washing 
with ethanol according to the manufacturer´s instructions. RNA pellets were dried and 
resuspended in 10-40 µl DEPC-H2O depending on the size of the pellet. RNA 
concentration and purity was determined using a spectrophotometer. 10 µg total RNA 
were digested with 10 U Rnase-free DNase I (Roche, Mannheim, Germany) in a total 
volume of 20 µl 1 x DNase I digestion buffer. 
 
10 x DNase I digestion buffer: Tris (pH 7.4)   10 mM 
      MgCl2    10 mM 
 
DNase digest was carried out at 37°C for 60 min. The enzyme was inactivated at 75°C 
for 10 min. RNA was stored at –20°C. 
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3.5.1.2 Reverse transcription of mRNA and PCR from cDNA 
 
2.5 µg DNase I digested RNA were reverse transcribed to cDNA for 60 min at 37°C. 
 
volume reagent concentration 
5.3 µl H2O-DEPC 0.1% diethylpyrocarbonate 
1.6 µl Oligo dT (15 T) 500 µg/ml 
4 µl 5x first strand buffer 250 mM Tris-HCl, pH 8.3; 375 mM KCl; 15 mM MgCl2 
2 µl DTT 0.1 M 
0.1 µl M-MLV RTase 200 U/µl 
5 µl total RNA 0.5 µg/µl 
M-MLV RTase was inactivated at 95°C for 10 min. cDNA was stored at –20°C.  
 
PCR from cDNA was performed under the same conditions as PCR from DNA described 
in 3.4.1.2. ß-Actin PCR was performed from DNase I digested RNA as well as from 
cDNA to detect genomic DNA contamination or the loss of integrity of the cDNA. 
 
3.6 Evaluation of gene expression at the protein level 
 
3.6.1 Western Blot 
 
3.6.1.1 Extraction of protein from tissue samples 
 
Tissue samples stored at –80°C were weighed, transferred to 10 ml roundbottom tubes 
containing extraction buffer and homogenized in a polytron blender at at 26,000 rpm 
(position E for skin) or at 23,500 rpm (position D for muscle, heart, liver, kidney, 
mamma, lung, brain and gonads) for 1-2 min. For each 20 mg tissue, 500 µl extraction 
buffer were used.  
 
Protein extraction buffer:  5 x Laemmli buffer 20%   
     Tris (pH 7.4)  20 mM 
     Triton X-100  2% 
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The homogenizer was cleaned after each sample with distilled water and PBS. 
 
Phosphate-buffered saline (PBS): NaCl   8 g/l 
     KCl   0.2 g/l 
     Na2HPO4  1.44 g/l 
     KH2PO4  0.24 g/l 
The pH was adjusted to 7.4. 
 
Samples were transferred to 1.5 microfuge tubes, boiled at 95°C for 5 min and chilled on 
ice. In an end-over-end shaker, samples were incubated over night at 4°C. Samples were 
thereafter boiled again for 5 min at 95°C, chilled on ice and centrifuged at 12,000 rpm, at 
4°C for 5 min. An aliquot was removed for determination of protein concentration. 
Samples were stored at –20°C. 
 
3.6.1.2 Determination of protein concentration 
 
Protein concentration was measured using the bicinchoninic acid (BCA) protein assay. A 
set of protein standards of known concentration was prepared by serially diluting a 
bovine serum albumin (BSA) stock solution (4 mg/ml) in PBS. 50 µl of the standards and 
of the samples (diluted 1:10 in PBS) were pipetted into a 96-well plate. 200 µl 
bicinchoninic acid solution containing 4% CuSO4 were added to each well. The plate was 
incubated at 37°C for 30 min. The absorbance at 562 nm (absorbance maximum for 
BCA-Cu1+ complexes generated as consequence of reduction of Cu2+ to Cu1+ by proteins) 
was measured in a spectrophotometer. A standard curve was prepared by plotting the 
absorbance of standards versus protein concentration. Using the standard curve, the 
protein concentration of the samples was determined. 
 
3.6.1.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Proteins were separated according to their molecular weight on SDS-polyacrylamide gels 
in the Mini Protean II System (Bio-Rad, Munich, Germany). First, the separating gel was 
prepared in an Erlenmeyer flask under continuous agitation and poured into the gap 
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between the glass plates of the system, leaving enough space for the stacking gel. The 
separating gel was immediately overlaid with bidistilled water. 
 
Separating gel (12%): Bidistilled water 3.35 ml 
(for 2 gels)   1.5 M Tris pH 8.8 2.5 ml 
    30% Acrylamide 4 ml 
    10% SDS  100 µl 
    Temed   5 µl 
    10% APS  50 µl 
 
After 45 min polymerisation at RT, the water was discarded. The stacking gel was 
prepared in the same way and loaded on the top of the separating gel. The comb was 
inserted without trapping air bubbles. 
 
 Stacking gel (5%):  bidistilled water 7.0 ml 
(for 4 gels)   0.5 M Tris pH 6.8 1.25 ml 
    30% Acrylamide 1.5 ml 
    10% SDS  100 µl 
    Temed   5 µl 
    10% APS  100 µl  
 
After 30 min polymerisation at RT, the gels were mounted in the electrophoresis chamber 
which was then filled with electrophoresis buffer. Combs were removed carefully and 
wells were washed immediately with a pasteur pipette containing electrophoresis buffer. 
Air bubbles at the bottom of the gels were flushed away with a syringe. 
 
Electrophoresis buffer:  Tris  30.3 g/l 
    Glycine 144 g/l 
    SDS  10 g/l 
 
Gel slots were loaded with 5-30 µl of the protein extract corresponding to 50-80 µg of 
protein. A low range protein marker covering molecular weights between 6.5 and 66 kD 
was used for estimation of protein size. Electrophoresis was carried out at 100 V for 10 
min and then at 160 V until the bromophenol blue reached the bottom of the separating 
gel. 
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3.6.1.4 Electroblotting 
 
The separated proteins were transferred from the gel to a polyvinylidendiflouride (PVDF) 
membrane (Immobilon-P®, Millipore, MA, USA) by semidry electroblotting. The 
membrane was cut to the size of the gel, preincubated for 10 min in absolute methanol 
and subsequently incubated in transfer buffer for 30 min at RT. 
 
Transfer buffer: Methanol 20% 
   Tris  5.82 g/l 
   Glycine 2.92 g/l 
   SDS  0.37 g/l 
 
12 pieces Whatman blotting paper were cut to the size of the membrane and soaked in 
transfer buffer. 6 pieces were stacked, one on top of the other, on the anode of a graphite 
electroblotter (Millipore, Ma, USA). PVDF membrane and gel were added and another 6 
pieces of wet blotting paper were stacked exactly on top. Layers were repeatedly 
squeezed with a pipette to remove air bubbles. The cathode was placed on top. Transfer 
took place for 90 min at 1 mA/cm2 gel plane. After the transfer, the membrane was 
stained with Ponceau red for 2 min, rinsed with bidistilled water and dried. Molecular 
weight markers were labeled with a pen. Membranes were stored at 4°C. 
 
Ponceau red:  Ponceau S 2 g/l 
   Acetic acid 30% 
 
3.6.1.5 Protein detection by peroxidase-labeled antibodies 
 
Membranes were incubated in a hybridization oven with blocking solution for 1 h at RT. 
 
Blocking buffer: Spray dried skimmed milk    3% 
   Tween 20 (polyoxyethylene sorbitol-monolaurate) 0.1% 
   TBS (Tris-buffered saline) 
 
After blocking, the membrane was washed 3 times (1 x 15 min; 2 x 5 min) with Tris-
buffered saline containing 0.1% Tween 20 (TBS-T 0.1%) at RT in an incubation oven. 
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TBS-T 0.1%:  Tris (pH 7.4) 3 g/l    
(Washing buffer) NaCl  8 g/l 
   Tween 20  0.1% 
 
The membrane was incubated with the primary antibody (rabbit anti-EGFP antibody, 
purified IgG fraction, Molecular probes) diluted 1:1,000 in blocking buffer for 2 h at RT. 
Three washing steps with TBS-T 0.1% were subsequently performed as described above. 
Incubation with the second antibody (peroxidase-conjugated, affinity-purified goat anti-
rabbit antibody, Jackson Immuno Research distributed by Dianova, Hamburg, Germany) 
diluted 1:5,000 in blocking buffer was performed for 1.5 h at RT. Finally, membranes 
were washed 5 times (1 x 15 min, 4 x 5 min) at RT. Detection of peroxidase activity was 
performed by incubating the membrane with 3 ml of ECL Western blotting detection 
reagent (Amersham Pharmacia, Freiburg, Germany). The membrane was mounted on a 
glass plate, sealed with Saran wrap and exposed to an ECL film (Amersham Pharmacia, 
Freiburg, Germany). 
 
3.6.2 Histology 
 
3.6.2.1 Collection and fixation of tissues 
 
At the age of 10 to 12 weeks, mice were put to ether anesthesia, killed by cervical 
dislocation and dissected. Pieces of muscle, gonads, liver, lung and brain were collected 
and directly processed for histology. Histology was carried out in cooperation with the 
Institute of Histology of the VU (Veterinärmedizinische Universität) Vienna. As positive 
control in histology, the institute provided EGFP expressing tumor tissue 
(precWAPeGFP transfected MCF7-tumor xenografts). 
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Organs were fixed in 4% buffered formaldehyde for 6 h at RT and embedded in paraffin. 
Embedding times and solvents were as follows: 
 
Solvent Time Temperature 
Ethanol 70% 1 hour 55°C 
Ethanol 80% 1 hour 55°C 
Ethanol 96% 1 hour 55°C 
Ethanol 96% 1 hour 55°C 
Ethanol 100% 1 hour 55°C 
Ethanol 100% 1 hour 55°C 
Xylene 1 hour 55°C 
Xylene 1 hour 55°C 
Paraffin (melting point 50-52°C) Over night 50°C 
 
Paraffin (melting point 56°C) and specimen were thereafter blocked in a mold. 
 
3.6.2.2 Preparation of slides 
 
Glass slides for immunohistochemical staining were pretreated with poly-L-lysine to 
improve adhesion of tissue on glass. These slides were incubated for 5 min at RT in a 
10% poly-L-lysine solution (Sigma, Taufkirchen, Germany). Glass slides for 
haematoxylin & eosin, mowiol and propidium iodide staining were not pretreated. From 
each organ, five 5 µm thick sections were cut. The paraffin ribbons were floated on 
deionized water (45°C) and mounted on the appropriate glass slides. Sections were dried 
over night at 55°C. All slides were deparaffinized and rehydrated as follows: 2 x 5 min 
xylene, 2 x 2 min 100% ethanol, 2 min 96% ethanol, 2 min 70% ethanol. 
 
Sections for mowiol and propidium iodide staining were furthermore incubated for 2 min 
in bidistilled water. 
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3.6.2.3 Haematoxylin & eosin staining 
 
One deparaffinated and rehydrated section of every organ was incubated for 3 min in 
Mayer´s hemalum (Merck, Wertheim, Germany), rinsed in tap water for 5 min, incubated 
for 3 min in Eosin Y solution (Merck, Wertheim, Germany) and for 1 min in 0.1% acetic 
acid. Sections were dehydrated in an ascending series of ethanol (3 min ethanol 70%, 3 
min ethanol 96% and 3 min ethanol 100%), incubated in xylene for 2 min and mounted 
with Entellan® (Merck, Wertheim, Germany). Slides were stored in the dark at +4°C until 
histological investigation. 
 
3.6.2.4 Mowiol and propidium iodide staining 
 
One deparaffinized and rehydrated section of every organ was mounted in anti-fading 
medium (mowiol solution). Another section of every organ was treated with propidium 
iodide to stain cell nuclei, at 1:10,000 dilution in bidistilled water for 2 min at RT and 
thereafter mounted with 1-2 drops of mowiol solution. Slides were stored in the dark at 
+4°C until histological investigation. 
 
Mowiol solution: Mowiol 4-88 29 g 
   in 80 ml PBS  
The solution was stirred for 12 h at RT before adding 40 ml glycerol. After another 12 h 
of stirring at RT and centrifugation for 1 h at 15,000 rpm, the supernatant was recovered, 
supplemented with NaN3 and stored at +4°C. 
 
 
3.6.2.5 Immunohistochemical staining 
 
Deparaffinized sections were pretreated with 0.6% hydrogen peroxide in methanol for 15 
min to inactivate endogenous peroxidase and rinsed with tap water. Slides were then put 
into an immunostaining centre where all the following steps were accomplished. Slides 
were incubated with 1.5% normal goat serum for 30 min at RT to minimize unspecific 
background staining. The primary antibody, rabbit anti-GFP (Molecular probes, Leiden, 
Niederlande), was diluted in phosphate-buffered saline (PBS) to a final concentration of 
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1:4,000. Slides were incubated with the primary antibody overnight at +4°C. On the next 
day, slides were washed with PBS and covered with EnVision+TM solution, containing a 
goat anti-rabbit antibody conjugated to peroxidase, (DAKO, CA, US) for 30 min at RT. 
After that, sections were washed with PBS and slides developed for 10 min at RT in 0.1% 
3.3´-diaminobenzidine (DAB) hydrochloride containing 0.03% hydrogen peroxide. The 
reaction was stopped in bidistilled water for 5 min. Finally, sections were counterstained 
with Mayer´s hemalumn, dehydrated and mounted in DPX medium.  
 
DPX:  contains distyrene 
  plasticizer (tricresyl phosphate) 
  xylene  
Slides were stored in the dark at +4°C until histological investigation. 
 
3.6.2.6 Histological investigation of tissues 
 
Histological investigation of tissues was carried out under a Zeiss axiovert 200-N 
microscope (Zeiss, Jena, Germany). Pictures were taken with an Axiocam (Zeiss, Jena, 
Germany). Sections stained with haematoxylin & eosin and immunohistochemistry were 
evaluated by bright field microscopy at 400x and 1000x magnification. All sections 
mounted with mowiol, including those counterstained with propidium iodide, were 
investigated by fluorescence microscopy at 400x magnification to detect native EGFP 
fluorescence. EGFP fluorophores were excited with ultraviolet light passing through a 
450-490 nm filter (FT 510/LP520). 
 
3.7 Phenotypic consequences of transgene expression 
 
3.7.1 Analysis of body weight, body length and organ weights 
 
At the age of 10 to 12 weeks, mice were put to ether anesthesia, sacrificed by cervical 
dislocation and weighed entirely. The length from the distal end of the nose to the 
proximal end of the tail was measured (nose-rump length). The following organs were 
removed quickly and directly put on dry ice to freeze to –80°C: tail, skin from the back, 
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tissue from all 12 mammary complexes, the musculus quadriceps, the gonads, spleen, 
both kidneys, liver, heart, lung and brain. Partly, complete organs were weighed after 
removing surplus blood by softly pressing pieces to a kimwipe (gonads, pancreas, spleen, 
both kidneys, liver, lobus thoracicus dexter and sinister of the thymus, heart, lung, brain). 
Additionally, pieces from muscle, liver, gonads, lung and brain were fixed in 4 % PBS-
buffered formaldehyde (pH 7) for histological examination. 
 
3.8 Statistics 
 
The data was analyzed for significance of differences using a two tailed Student´s t-test. 
A difference was considered to be statistically significant at p< 0.05. 
 
 
3.9 Equipment and reagents 
 
Company  Reagent/ device Catalogue number 
Air liquide 
Muenchen, Germany 
 
Dry ice slices 400101 
Amersham Pharmacia 
Freiburg, Germany 
Rapid-Hyb hybridisation 
buffer 
ECL western blotting reagent 
ECL X-ray film 
Micro Spin S-300 columms 
 
RPN 1636 
RPN 2109 
RPN 2103 K 
27-5/30-01 
ART Labortechnik 
Mülheim, Germany 
 
Tissue homogenizer  
Bachhofer 
Reutlingen, Germany 
 
Hybridization oven (Mini 38)  
Beckmann 
CA, US 
 
Spectrophotometer DU640 
Scintillation counter 
 
Bio-Rad 
Munich, Germany 
Mini Protean System 
30% acrylamide 
ammonium persulfate 
Temed 
POWER PACK 300  
 
161-0156 
161-0700 
161-0800 
165-5050 
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tissue from all 12 mammary complexes, the musculus quadriceps, the gonads, spleen, 
both kidneys, liver, heart, lung and brain. Partly, complete organs were weighed after 
removing surplus blood by softly pressing pieces to a kimwipe (gonads, pancreas, spleen, 
both kidneys, liver, lobus thoracicus dexter and sinister of the thymus, heart, lung, brain). 
Additionally, pieces from muscle, liver, gonads, lung and brain were fixed in 4 % PBS-
buffered formaldehyde (pH 7) for histological examination. 
 
3.8 Statistics 
 
The data was analyzed for significance of differences using a two tailed Student´s t-test. 
A difference was considered to be statistically significant at p< 0.05. 
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Company  
 
Reagent/ device Catalogue number 
Biometra 
Göttingen, Germany 
 
UNO II thermocycler   
DAKO corporation 
CA, US 
 
EnVision+ antibody  
DIFCO 
Le Pont de Claix, France 
Tryptone peptone 
Yeast extract 
Agar, granulated 
 
123-17-0 
0127-17-9 
0145-17-0 
Dow chemicals Company 
MI, USA 
 
Saran Wrap  
Electron Microscopy Sc. 
PA, US 
 
DPX mountant 13510 
Eppendorf 
Hamburg, Germany 
1.5 centrifuge tubes 
2.0 centrifuge tubes 
thermomixer type 5436 
centrifuge type 5417R 
 
0030 120.086 
0030120.094 
Genomed 
Bad Oeyenhausen, 
Germany 
 
Jetsorb kit 110150 
Greiner 
Frickenhausen, Germany 
 
Petri dishes 90 mm, sterile 663161 
Invitrogen 
Paisley, Scotland 
 
MLV-Reverse Transcriptase 28025013 
Kisker 
Steinfurt, Germany 
 
Quali-PCR tubes G002-A 
MBI fermentas 
St Leon-Rot, Germany 
PUC Mix Marker 
6x loading dye 
1 kb ladder 
Eco RI (HC) 
Bam HI (HC) 
Not I 
Xho I 
Sca I 
 
 
SM 0301 
R 0611 
SM 0312 
ER 0273 
ER 0053 
ER 0591 
ER 0691 
ER 0432 
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Company  
 
Reagent/ device Catalogue number 
MBI fermentas 
St Leon-Rot, Germany 
Hind III 
Klenow fragment exo- 
Hexa Label DNA labeling kit  
 
ER 0503 
EP0422 
K 0612 
Merck 
Wertheim, Germany 
Glycerol 
Mayer`s hemalum 
Bomophenol blue 
Natrium chloride 
Natrium hydroxide 
Dodecyl sulfate sodium salt  
2-propanol (Isopropanol) 
Formaldehyde solution (37%) 
Chloroform 
Copper II sulfate 
Ethidiumbromide 1% 
Eosin Y solution 
Entellan 
 
4094 
1.09249 
8122 
1.06404 
1.06498 
1.13760 
1.09634 
1.04003 
1.02445 
2791 
1.11608.0030 
1.09844 
1.07961 
Millipore 
MA, USA 
Milliblot-Graphite 
Electroblotter 
Immobilon-P (PVDF) 
 
MBBDGE 001 
IPVH 00010 
Molecular probes 
OR, US 
 
Rabbit anti-GFP  
Pall 
NY, USA 
 
Biodyne (nylon membrane) P/N 60113 
Perkin Elmer 
MA, USA 
 
α32-P-dCTP PC 3919-0101 
Polysciences 
Eppelheim, Germany 
 
Mowiol 4-88 17951 
Promega 
WI, USA 
 
Wizard genomic DNA 
purification kit 
A 1120 
 
Quiagen 
Hilden, Germany 
 
Taq DNA polymerase 
QIAprep Minispin Kit 
201203 
27106 
Ratiolab 
Buchschlag, Germany 
 
Semperguard nitril gloves 
Safe skin latex gloves 
 
 
9900043 
220 
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Company  
 
Reagent/ device Catalogue number 
Roche 
Mannheim, Germany 
 
 
DNase I (RNase free) 
TriPure Isolation Reagent 
Sure cut buffer H 
776 785 
1667165 
1417991 
Carl Roth 
Karlsruhe, Germany 
Diethylpyrocarbonate (DEPC) 
Tris 
Glacial acetic acid 
Ethylenediamine-tetraacetic 
acid  
Methanol 
Glycine 
Kanamycin  
 
K 028.2 
4855.2 
3783.1 
8043.2 
4627.1 
3908.2 
832.1 
Sigma 
Taufkirchen, Germany 
Propidium Iodide 
Tween 20 
Potassium chloride (KCl) 
Calcium chloride (CaCl2) 
Proteinase K 
Triton X-100 
Protein LR Marker 
Bovine serum albumin 
 
P-4170 
P-1379 
P-4504 
C-7902 
P-6556 
X-100 
M-3913 
A-4503 
Sigma 
Taufkirchen, Germany 
Ponceau S 
3.3´-Diamonibenzidine 
Poly-L-Lysine 
Bicinchoninic acid solution 
Hepes 
 
P-3504 
D 5637 
P 8920 
B 9643 
H-4034 
Schleicher& Schuell 
Dassel, Germany 
 
Gel blotting paper GB 002 10426694 
Schubert and Weiss 
Muenchen, Germany 
 
Nunc cryo tubes 1.5 ml 375418 
Stratagene 
Heidelberg, Germany 
 
Eagle Eye II  
Vogel 
Gießen, Germany 
HistoComp  
Zeiss 
Jena, Germany 
Axiovert microscope 
200 – N 
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Results 67
4 RESULTS 
 
4.1 Purification of gene constructs for DNA microinjection 
 
Purification of the gene constructs pBL-HERV-L as well as pEGFP-HERV-H-H6 from 
agarose gels yielded high DNA quality for microinjection (Figure 10). 
 
Figure 10:  Agarose gel electrophoresis of the restiction enzyme digested plasmid  
pBL-HERV-L. M: molecular weight marker; 1, 2, 3, 4: pBL-HERV-L plasmid DNA;  
The 3.2 kb fragment of lane 2, 3 and 4 was cut out and and subsequently purified. 
 
4.2 Generation of transgenic animals and breeding of transgenic lines 
 
Transgenic animals were identified by PCR (Figure 11 and 12) from genomic DNA 
obtained from tail samples. The efficiency of gene transfer is displayed in Table 9. 
 
Table 9:  Efficiency of gene transfer in mouse for the constructs pBL-HERV-L and  
pEGFP-HERV-H-H6. 1recipients with litter/number of embryo tranfers; 2 number of 
transgenic animals after weaning/total number of animals after weaning.  
Gene construct Injected  
embryos 
Embryo 
transfers 
Pregnancy 
rate 1 
Integration 
rate 2 
Founder 
animals 
pEGFP-HERV-H-H6 238 11 82% 19% 10 
pBL-HERV-L 374 18 67% 26% 9 
3.2 kb
1.8 kb
1.2 kb
M 1 2 3 4
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Figure 11: Screening of pBL-HERV-L mice by PCR. Upper picture: Luciferase 
(reporter gene) PCR; Lower picture: ß-actin (housekeeping gene) PCR. M: DNA length 
marker; tg: transgenic mouse (line #6); wt: wildtype mouse; +: positive control;  
-: negative control. 
 
 
 
 
Figure 12: Screening of pEGFP-HERV-H-H6 mice by PCR. Upper picture: 
EGFP (reporter gene) PCR; Lower picture: ß-actin (housekeeping gene) PCR. M: DNA 
length marker; wt: wildtype mouse; tg: transgenic mouse (line #1, #5, #10); +: positive 
control; -: negative control; k: kawasaki buffer. 
 
ß-actin
613 bp
Luciferase
577 bp
m mtgtgtgtg wt + -wt
ß-actin
613 bp
EGFP
552 bp
m tg tg tg  k  + m-wt
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Founder mice were mated with C57BL/6 mice to generate transgenic lines. Four out of 
ten pEGFP-HERV-H-H6 transgenic founders showed germline transmission. From these 
founders, four transgenic lines were established (line #1, #5, #9, #10) (Table 10). One 
pBL-HERV-L founder animal transmitted the gene construct to its offspring, resulting in 
one pBL-HERV-L transgenic line (line #6) (Table 11).  
 
Table 10: Generation of pEGFP-HERV-H-H6 transgenic lines 
 
Founder No.  Mated Number of litters Tg offspring Line # 
610-9 + 2 + 1 
610-12 + 1 - 2 
609-5 + 0 - 3 
609-6 + 1 - 4 
708-50 + 2 + 5 
610-14 + 1 - 6 
610-16 + 1 - 7 
704-21 + 2 - 8 
704-22 + 1 + 9 
706-26 + 1 + 10 
 
Table 11: Generation of pBL-HERV-L transgenic lines 
 
Founder No.  Mated Number of litters Tg offspring Line # 
614-1 + 2 - 1 
614-5 + 2 - 2 
614-6 + 3 - 3 
614-11 + 1 - 4 
614-3 + 1 - 5 
716-8 + 2 + 6 
716-11 + 2 - 7 
716-15 + 1 - 8 
717-16 + 2 - 9 
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Transgenic mice were bred with C57BL/6 mice to generation F2 to obtain 87.5% 
C57BL/6 genetic background. In all 4 pEGFP-HERV-H-H6 transgenic lines, the 
proportion of transgenic F1 animals from total F1 animals was below 50%. Maximum 
57% transgenic pEGFP-HERV-H-H6 mice were born in generation F2. The proportion of 
pBL-HERV-L transgenic mice from total mice was below 50% in both generation F1 and 
F2 (Table 12 and 13).  
 
Table 12:              Transmission rates of transgenes in generation F1  
 
gene construct line # founder total mice 
in generation F1 
transgenic mice (%) 
in generation F1 
pEGFP-HERV-H-H6 1 610-9 11 4 (36%) 
pEGFP-HERV-H-H6 5 708-50 12 4 (33%) 
pEGFP-HERV-H-H6 9 704-22 11 3 (27%) 
pEGFP-HERV-H-H6 10 706-26 11 2 (18%) 
pBL-HERV-L 6 716-8 14 5 (35%) 
 
Table 13:               Transmission rates of transgenes in generation F2 
 
gene construct line # F1 mouse total mice 
in generation F2 
transgenic mice (%) 
in generation F2 
pEGFP-HERV-H-H6 1 610-9-1 7 4 (57%) 
pEGFP-HERV-H-H6 5 708-50-7 9 4 (44%) 
pEGFP-HERV-H-H6 9 704-22-10 11 2 (18%) 
pEGFP-HERV-H-H6 10 706-26-10 8 3 (37%) 
pBL-HERV-L 6 716-8-4 / -5 18 8 (44%) 
 
 
The breeding data obtained in generation F1 and F2 indicates one integration site of the 
pEGFP-HERV-H-H6 and the pBL-HERV-L construct. 
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Further characterization of transgene integration was performed in pEGFP-HERV-H-H6 
mice by Southern blot analysis of DNA isolated from liver tissue (Figure 14). Genomic 
DNA of transgenic and wildtype mice was digested using Hind III and Eco RI. The 
positive control, pEGFP-HERV-H-H6 plasmid DNA (4,151 bp), was linearized with 
Hind III. The radioactively labelled probe (720 bp) hybridized with the EGFP reporter 
gene (Figure 13). 
 
Figure 13: Restriction enzyme sites in the pEGFP-HERV-H-H6 gene construct and  
alignment of the radioactively labelled probe with the transgene in Southern blot analysis. 
 
Figure 14: Southern blot analysis of genomic DNA from pEGFP-HERV-H-H6 mice. 
 
By displaying single bands, Southern blot analysis of genomic DNA indicated in all 
tested transgenic lines of pEGFP-HERV-H-H6 mice a single integration site of the 
transgene. 
Hind III
pos. 416
Eco RI
pos. 4380 1455
HERV-LTR EGFP
probe
L10 L5 L1 L10 L5 L1wt wt plasmid
4000 bp
2500 bp
2000 bp
1500 bp
Eco RIHind III Hind III
wt: wildtype mice
L1, L5, L10: EGFP transgenic mice lines #1, #5, #10
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4.3 Expression studies  
 
Expression studies at mRNA level were performed in pBL-HERV-L and pEGFP-HERV-
H-H6 mice of both sexes at the age of 10 to 12 weeks. The following organs were used 
for isolation of RNA: muscle, heart, liver, kidney, spleen, skin, mammary gland, lung, 
brain (without pituitary gland) and gonads. Absolute body weight, nose rump length 
(NRL) and organ weights were determined (Table 14 and 15). These phenotypic traits of 
transgenic and wildtype mice were subjected to statistical analysis. No significant 
differences were observed between transgenic mice and their non-transgenic littermates. 
Therefore, no indication for insertional mutagenesis was provided. 
 
Table 14: Body weight, nose rump length (NRL) and organ weights of pEGFP-
HERV-H-H6 transgenic mice and their control littermates at the age of 10 
to 12 weeks. The values represent the mean ± standard deviation (SD). 
 
Parameter  male tg 
(n=6) 
male wt 
(n=3) 
female tg 
(n=6) 
female wt 
(n=3) 
Body weight  [g] 24.52 + 1.5 26.06 + 1.1 20.70 + 1.5 20.95 + 2.4 
NRL  [cm] 9.36 + 0.3 9.70 + 0.2 8.60 + 0.1 8.90 + 0.4 
Gonads  [mg] 199.30 + 14.6 191.30 + 10.0 20.00 + 2.7 21.67 + 2.8 
Pancreas  [mg] 141.33 + 17.6 155.33 + 13.2 128.16 + 10.3 146.00 + 5.1 
Spleen  [mg] 68.83 + 9.2 79.66 + 9.6 75.33 + 9.8 80.66 + 22.7 
Liver [g] 1.46 + 0.1 1.48 + 0.3 1.12 + 0.1 1.18 + 0.22 
Thymus [mg] 48.00 + 7.4 42.5 + 3.5 59.83 + 19.7 57.33 + 6.4 
Heart [mg] 164.33 + 33.7 171.67 + 19.8 147.00 + 32.1 140.00 + 9.0 
Lung [mg] 155.30 + 12.6 157.00 + 12.1 139.80 + 18.2 161.3 + 3 5.9 
Brain [mg] 373.33 + 44.0 398.33 + 53.4 400.67 + 34.5 373.33 + 31.2 
Kidney* [mg] 176.00 + 16.4 188.33 + 10.4 137.00 + 8.7 152.00 + 9.8 
* Arithmetic mean of both kidney weights 
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Thymus [mg] 48.00 + 7.4 42.5 + 3.5 59.83 + 19.7 57.33 + 6.4 
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Brain [mg] 373.33 + 44.0 398.33 + 53.4 400.67 + 34.5 373.33 + 31.2 
Kidney* [mg] 176.00 + 16.4 188.33 + 10.4 137.00 + 8.7 152.00 + 9.8 
* Arithmetic mean of both kidney weights 
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Table 15: Body weight and organ weights of pBL-HERV-L transgenic mice and 
their control littermates at the age of 10 to 12 weeks. The values represent 
the mean ± standard deviation (SD) 
 
Parameter  male tg 
(n=4) 
male wt 
(n=3) 
female tg 
(n=3) 
female wt 
(n=4) 
Body weight  [g] 27.15 + 0.9 26.06 + 1.1 19.82 + 2.5 21.65 + 2.4 
Spleen  [mg] 78.77 + 12.7 79.66 + 9.6 75.5 + 9.8 82.77 + 19.0 
Liver [g] 1.34 + 59.3 1.48 + 0.3 1.09 + 0.0 1.18 + 0.2 
Heart [mg] 129.8 + 11.0 171.67 + 19.8 104.53 + 3.0 133.45 + 15.0 
Kidney* [mg] 169.15 + 2.9 188.33 + 10.4 121.16 + 5.9 147.93 + 9.9 
* Arithmetic mean of both kidney weights 
 
 
 
 
Figure 15: Total RNA isolated from mouse tissue 
  
RNA was extracted from all tissues (Figure 15) and subjected to RT-PCR. pEGFP-
HERV-H-H6 transgenic mice of lines #1, #5 and #10 showed expression of mRNA in 
muscle, liver, gonads, brain and lung (Table 16). In line #5 mRNA was additionally 
found in heart, kidney, mammary gland and spleen (Figure 16). In line #9 no 
transcription of EGFP was present. pBL-HERV-L transgenic mice of line #6 did not 
display pBL-RNA in any tissue (Figure 17). 
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Table 16:  RT-PCR results indicating expression of EGFP mRNA in different organs  
of pEGFP-HERV-H-H6 transgenic mice. +: presence of EGFP cDNA 
amplikon; -: absence of EGFP cDNA amplikon.*ß-actin RT-PCR negative 
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Line #1 + - + - - - - - + + 
Line #5 + + + + + -* + + + + 
Line #9 - - - - - - - - - - 
Line #10 + - + - - - - + + + 
 
Figure 16: RT-PCR from a wildtype and a pEGFP-HERV-H-H6 transgenic 
mouse of line #5 
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Figure 17: RT-PCR from pBL-HERV-L transgenic mice 
 
 
Expression studies at the protein level were carried out in pEGFP-HERV-H-H6 mice of 
lines #1, #5 and #10. RNA-positive organs such as muscle, liver, gonads, brain and lung 
were examined for EGFP protein expression in F2 mice of both sexes at the age of 10 to 
12 weeks. Western blot and histology were performed in two transgenic animals of each 
transgenic line and two wildtype mice. Expression of EGFP protein was detectable by 
Western blot in testis tissue of line #5 and #1 mice (Figure 18). 
 
 
 
m
ar
ke
r
m
ar
ke
r
m
us
cl
e
he
ar
t
liv
er
lu
ng
br
ai
n
ki
dn
ey
sp
le
en
sk
in
m
am
m
a 
te
st
is
+ -
ß-actin PCR
from DNAse 
digested RNA
ß-actin PCR 
from cDNA
613 bp
Luciferase PCR
from cDNA
 577 bp
+: positive control
-: negative control
positive control for ß-actin PCR and RT-PCR: mouse genomic DNA
positive control for Luciferase RT-PCR: pBL-HERV-L plasmid DNA
negative control : H2O
+ -+ - m
ar
ke
r
Results 75
 
Figure 17: RT-PCR from pBL-HERV-L transgenic mice 
 
 
Expression studies at the protein level were carried out in pEGFP-HERV-H-H6 mice of 
lines #1, #5 and #10. RNA-positive organs such as muscle, liver, gonads, brain and lung 
were examined for EGFP protein expression in F2 mice of both sexes at the age of 10 to 
12 weeks. Western blot and histology were performed in two transgenic animals of each 
transgenic line and two wildtype mice. Expression of EGFP protein was detectable by 
Western blot in testis tissue of line #5 and #1 mice (Figure 18). 
 
 
 
m
ar
ke
r
m
ar
ke
r
m
us
cl
e
he
ar
t
liv
er
lu
ng
br
ai
n
ki
dn
ey
sp
le
en
sk
in
m
am
m
a 
te
st
is
+ -
ß-actin PCR
from DNAse 
digested RNA
ß-actin PCR 
from cDNA
613 bp
Luciferase PCR
from cDNA
 577 bp
+: positive control
-: negative control
positive control for ß-actin PCR and RT-PCR: mouse genomic DNA
positive control for Luciferase RT-PCR: pBL-HERV-L plasmid DNA
negative control : H2O
+ -+ - m
ar
ke
r
 Results 76
 
Figure 18: Western blot of testis of pEGFP-HERV-H-H6 transgenic mice 
 
Histological sections from muscle, liver, gonads, brain and lung were prepared according 
to Walter et al. (2001). Four stainings of each organ were evaluated under the 
microscope: 
 
• Native section mounted in mowiol 
• Native section counterstained with propidium iodide and mounted in mowiol 
• Immunohistochemistry 
• Haematoxylin & eosin staining. 
 
In the testis of line #5 pEGFP-HERV-H-H6 transgenic mice, the Leydig cells (Figure 19) 
appeared EGFP positive in mowiol and propidium iodide/mowiol treated sections 
(Figures 20 and 21). This could not be confirmed by immunohistochemistry (Figure 22).  
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Figure 19: Haematoxylin & eosin staining of seminiferous tubules and intertubular 
tissue in mouse testis. The intertubular tissue contains clusters of Leydig 
cells, blood vessels, a lymphatic system, macrophages and fibroblasts 
within a loosely arranged matrix. The seminiferous tubules contain 
different types of germ cells. 
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Figure 19: Haematoxylin & eosin staining of seminiferous tubules and intertubular 
tissue in mouse testis. The intertubular tissue contains clusters of Leydig 
cells, blood vessels, a lymphatic system, macrophages and fibroblasts 
within a loosely arranged matrix. The seminiferous tubules contain 
different types of germ cells. 
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Figure 20:   Native section of testis mounted in mowiol. The wildtype mouse 
(bottom picture) displays less fluorescence than the EGFP-HERV-H-H6 transgenic  
mouse of line #5 (top picture). 
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Figure 20:   Native section of testis mounted in mowiol. The wildtype mouse 
(bottom picture) displays less fluorescence than the EGFP-HERV-H-H6 transgenic  
mouse of line #5 (top picture). 
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Figure 21: Native section of testis mounted with mowiol. Nuclei are stained with  
propidium iodide. The wildtype mouse (bottom) displays no fluorescence, whereas the  
EGFP-HERV-H-H6 transgenic mouse of line #5 (top) exhibits green intertubular  
structures such as Leydig cells. 
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Figure 21: Native section of testis mounted with mowiol. Nuclei are stained with  
propidium iodide. The wildtype mouse (bottom) displays no fluorescence, whereas the  
EGFP-HERV-H-H6 transgenic mouse of line #5 (top) exhibits green intertubular  
structures such as Leydig cells. 
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Figure 21: Immunohistochemistry revealed no remarkable difference in color between 
Leydig cells of wildtype mice (bottom) and Leydig cells of pEGFP-HERV-H-H6 
transgenic mice of line #5 (top). EGFP positive cells are marked by peroxidase labeled 
antibodies. Oxidation of the substrate, 0.1% 3,3`-diaminobenzidine (DAB) 
hydrochloride, would result in brown color of the labelled cell.
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Figure 21: Immunohistochemistry revealed no remarkable difference in color between 
Leydig cells of wildtype mice (bottom) and Leydig cells of pEGFP-HERV-H-H6 
transgenic mice of line #5 (top). EGFP positive cells are marked by peroxidase labeled 
antibodies. Oxidation of the substrate, 0.1% 3,3`-diaminobenzidine (DAB) 
hydrochloride, would result in brown color of the labelled cell.
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5 DISCUSSION 
 
5.1 Analysis of transgene integration 
 
If a non-mosaic founder with one integration site of the transgene is mated to a wildtype 
animal, the expected number of transgenic animals in the F1 and in subsequent 
generations is 50% (Gannon et al., 1990). The proportion expected in the case of a non-
mosaic founder carrying two integration sites is 75%. As the proportion of transgenic F1 
animals obtained from founders with germline transmission did not differ significantly 
from 50%, one integration site is probable in each pEGFP-HERV-H-H6 transgenic line 
and in the pBL-HERV-L transgenic line. For the pEGFP-HERV-H-H6 transgenic lines 
#1, #5 and #10, Southern blot analysis confirmed the conclusion drawn from the breeding 
data by displaying single bands. 
 
5.2 Expression level and pattern in pBL-HERV-L transgenic mice 
 
From 9 transgenic founder mice, one transgenic line was bred to generation F2. Animals 
of generation F2 did not show expression of luciferase RNA in 10 investigated organs. 
The establishment of a single transgenic line allows only very limited conclusions on the 
activity of the HERV-L promoter. The only conclusion that can be drawn is that the 
promoter is not active in the investigated transgenic line. However, this might be due to 
position effects. As promoters and enhancers in the vicinity of the integration site can 
influence transgene expression (Hammes and Schedl, 2000), several lines have to be bred 
and evaluated to assess the activity and specificity of a gene construct. Although this 
possibility was not given, examination of mRNA expression in the available animals 
could be performed easily by RT-PCR, which yielded negative results. Further 
investigation of pBL-HERV-L animals was not carried out. 
 
Nevertheless, the idea to investigate the HERV-L promoter activity in conjunction with 
the luciferase reporter gene in the mouse remains very promising. In the transient 
transfection pBLuciferase assay published by Schoen et al. (2001) the HERV-L promoter 
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displayed high and specific activity in human keratinocytes (HaCaT cell line). This 
makes the HERV-L-LTR especially interesting for the regulation of therapeutic genes in 
the skin. The fact that gene expression is to be monitored with pBLuciferase comprises 
additional advantages:  
 
• The in vitro studies on promoter activity of the HERV-L-LTR have been carried out 
in exactly the same expression vector (pBL); 
• Luciferase is a very sensitive reporter gene, allowing to exactly quantify even small 
amounts of protein;  
• Imaging of bioluminescence in the skin of living mice should easily be achieved by 
systemic administration of luciferin (Honigman et al., 2001) and subsequent 
measurement of luminescence.  
 
As a consequence of these considerations, we have continued to generate pBL-HERV-L 
transgenic mice. New lines of pBL-HERV-L transgenic mice will be examined in the 
near future to gain certainty about the promoter qualities of the HERV-L-LTR in vivo. To 
recognize position effects, more lines have to be established. 
 
 
5.3 Expression level and pattern in pEGFP-HERV-H6 transgenic mice 
 
From 10 transgenic founders, 4 transgenic lines were bred (#1, #5, #9, #10). mRNA 
expression was found in muscle, liver, gonads, brain and lung of transgenic mice from 
lines #1, #5 and #10. Animals of line #9 did not express EGFP-mRNA. They were not 
further investigated. F2 animals of both sexes of lines #1, #5 and #10 were examined for 
EGFP by Western blot and histology. In Western blot analysis only mice of the lines #1 
and #5 showed expression of EGF-protein in testis. In mowiol and propidium iodide/ 
mowiol stained histological sections of testis, the Leydig cells appeared EGFP positive in 
line #5. This could not be confirmed by immunohistochemistry.  
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The fact that animals of line #9 did not express EGFP could be due to position effects. 
However, more factors can influence the level of transgene expression. The most 
important factor appears to be the integration site (position effect), but also copy number 
and DNA methylation play a decisive role. In some reviews, the number of inserted 
copies of the transgene is reported to have no influence on transgene expression (Gannon 
et al., 1990). This has been disproved by Garrick et al. (1998). Using the lox/Cre system 
of site-specific recombination, they generated transgenic mouse lines in which different 
numbers of a transgene were present at the same chromosomal location. Reduction in 
copy number resulted in a marked increase in expression of the transgene. Expression of 
the transgene can also be influenced by DNA methylation (Reik et al., 1987). This 
epigenetic modification, which is associated with the phenomenon of genetic imprinting, 
can completely repress the expression of a gene construct (Jaenisch, 1997). 
 
A clear conclusion can be drawn from the positive Western blot results: EGFP is present 
in testis of line #1 and #5 mice. Looking only at the Western blot result, activity of the 
HERV-H-H6 LTR in testis could be explained by the fact that the LTR showed high 
activity in vitro in a germ cell tumor cell line (human teratocarcinoma cell line: 
NTera2D1; Feuchter and Mager, 1990). However, as histology indicates, the LTR is 
active in Leydig cells and not in germ cells. The fact that the HERV-H-H6 LTR drives 
expression in Leydig cells has to be explained differently. The steroid regulatory 
sequence TGTTCT is present in the HERV-H-H6 LTR as well as in HERV-R LTR. 
HERV-R is strongly expressed in human placenta and human adrenal gland. It is 
discussed in relation with differentiation and steroid hormone production by 
adrenocortical cells (Katsumata et al., 1998). Leydig cells are responsible for the 
production of the steroid hormone testosterone in the male mouse. The promoter activity 
of the HERV-H-H6 LTR could be linked to steroid hormone production. As a 
consequence, the HERV-H-H6 LTR should be active in the cortex of the adrenal gland 
(produces steroid hormones like aldosteron and cortisol), the ovary (produces the steroid 
hormone estrogen) and the placenta (produces estrogen), too. Why has no EGFP 
expression been reported in these organs? Unfortunately, neither adrenal gland nor 
placenta have been examined. Why was no EGFP expression detected by Western blot in 
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protein extracts of ovaries? This could simply be a quantity problem. As one ovary from 
each mouse was embedded for histology, there was only one (approx. 10 mg) ovary left 
for extraction of both RNA and protein. Detection of EGFP protein by Western blot is 
recommended (Living Colors® User Manual) for 25-75 µg of protein per polyacrylamid 
gel lane. The amount of ovary protein (80 ng/lane to 144 ng/lane) subjected to SDS-
PAGE was much smaller than the amount of testis protein (60 µg/lane to 80 µg/lane). In 
addition, theca cells represent only a small fraction of the total ovary cells.  
 
The histological methods to visualize EGFP in mouse tissue (Walter et al., 2000) have to 
be discussed critically. Paraffin embedded sections are known to increase background 
fluorescence (Ikawa et al., 1999) and GFP is unlikely to withstand the complete 
dehydration required for paraffin embedding (Living Colors User Manual, 2001). 
Nevertheless, Walter et al. (2000) published the detection of the reporter gene in paraffin 
sections form organs of CMV-EGFP transgenic mice. Native tissue sections mounted in 
mowiol and propidium iodide/mowiol showed EGFP fluorescence in the same pattern as 
visualized by immunohistochemistry. Only in weakly expressing tissue such as nerves, 
ganglia and submandibular gland, immunohistochemistry indicated EGFP expression 
while no fluorescence was detected by fluorescence microscopy. The authors suggested 
that the very low amount of EGFP, expressed in these tissues, could only be detected by 
the more sensitive immunohistochemical staining. A very impressive aspect of this 
publication surely is the broad spectrum of investigated organs (25 organs). The intention 
to produce paraffin sections, exhibiting excellent morphological preservation of tissue for 
better localization of EGFP expressing cells, is also understandable. However, the fact 
that EGFP was driven by the strong CMV promoter restricts the applicability of the 
published method. Investigators of EGFP transgenic mice with weaker promoters than 
CMV (and thus weaker EGFP expression) could easily be troubled with the distinction 
between the strong autofluorescence, due to paraffin embedding, and the weak EGFP 
fluorescence. Moreover, the announced conformity of EGFP fluorescence and 
immunohistochemistry is surely impressive, but no further investigations have been 
carried out. No Western blot or EGFP fluorometry results are available to confirm and 
quantify the merely optical impressions of microscopy. The relation of histology to 
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molecular biological investigation would have been especially interesting with regard to 
the pEGFP-HERV-H-H6 mice. 
 
Were the appropriate measures taken to investigate the promoter activity of the HERV-H-
H6 LTR? Generally the measures that were taken to investigate the expression pattern of 
EGFP-HERV-H-H6 transgenic mice have produced valuable hints about the activity of 
the HERV-H-H6 LTR promoter: RT-PCR and Western blot results indicated tissue 
specificity and histology indicated the corresponding cell type. Before, mice had been 
screened for transgenesis by PCR and Southern blot and bred to generation F2 to obtain 
an inbred strain dominated genetic background (87.5% C57BL/6). During dissection, 
transgenic mice were checked for phenotypic effects of insertional mutagenesis by 
determination of specific organ weight, body weight and body length. It is questionable 
to perform the labour intensive weighing of mouse organs during dissection, as most 
phenotypic effects only occur in homozygous, transgenic mice (Wagner et al., 1983). To 
round off the obtained results, it would be interesting to investigate a completed organ 
spectrum, including the cortex of the adrenal gland and the placenta, and to quantify the 
available EGFP by fluorometry.  
 
The original intention to measure the promoter activity of the HERV-H-H6 LTR in the 
transgenic mouse model with EGFP as reporter gene is actually conflicting. The available 
cell culture data on the promoter activity of the HERV-H-H6 LTR (Schoen et al., 2001) 
was obtained with the HERV-H-H6 LTR linked to another reporter gene than EGFP: to 
pBL. Influences of reporter genes on the promoters can never be excluded. The activity 
of the HERV-H-H6 LTR in different cell lines (Schoen et al., 2001) ranged from 20 % to 
100 % relative promoter activity. This is rather weak in comparison to the HERV-L LTR 
with 270 % relative promoter activity. The conjunction of a weak promoter to a EGFP 
reporter gene is critical. As EGFP is not an enzyme but a protein containing at most one 
chromophore, no amplification of signals helps to detect small amounts of protein. EGFP 
detection by fluorescence microscopy is limited by autofluorescence. Distributed in the 
cell cytoplasm, 4,000 molecules per cell are detectable (CLONTECHniques, 1997). 
When targeted to a defined subcompartment of the cell, already 300 molecules of EGFP 
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are visible (Shelby et al., 1996). Histological analysis of pEGFP-HERV-H-H6 transgenic 
mice can thus be problematic. Similar problems can be encountered with all discussed 
methods for detection of EGFP in the mouse: Whole body optical imaging (Yang et al., 
2000), fluorometry (Ikawa et al., 1995) and FACS analysis (Hadjantonakis and Nagy, 
2000) are all methods described for strongly expressing tissue. To exactly quantify 
fluorescence of pEGFP-HERV-H-H6 tissue, it might be necessary to first sort out the 
EGFP expressing cells from tissue by FACS analysis and to subsequently perform 
fluorometry from the concentrated, expressing cells. After all, the intention to evaluate 
the expression patterns of two HERV LTRs in vivo in two different reporter gene systems 
is not advantageous. Apart from the fact that the establishment of two different detection 
techniques is time consuming, different influences of the reporter genes on the promoter 
genes cannot be denied. A direct comparison of expression levels and patterns between 
HERV-H-H6 and HERV-L transgenic mice can thus not be performed. 
 
5.4 Final considerations 
 
Investigation of promoter activity and specificity of the HERV-L and the HERV-H-H6 
LTR in view to using them as control elements of therapeutic genes remains interesting. 
Now that the complete human genome is readily at hand, functional analysis of the 
indentified sequences is imperative. 1.8% of the human genome are retroviral LTRs.  
 
In gene therapy, the use of retroviral vectors as vehicles for the delivery of therapeutic 
genes is a promising alternative. The ability to target the delivery and expression of 
therapeutic genes in retroviral vectors in vivo is a prerequisite for their widespread and 
routine usage. However heterologous promoters, inserted into retroviral vectors for safety 
reasons, may interact with the retroviral LTRs and influence the expression of adjacent 
genes negatively (Wu et al., 1996). Localization of tissue specific regulatory elements in 
retroviral LTRs offer the possibility to replace the complete LTR of the gene vehicle by a 
tissue specific and highly active heterologous LTR (Leib-Mösch, 2000). As HERV LTRs 
contain all regulatory elements necessary to drive targeted gene expression, they are 
especially suitable for the use in retroviral vectors for gene therapy. 
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So far, only one HERV LTR transgenic mouse model has been published (Ting et al., 
1992). The in vivo models presented in this piece of work, offer further perspectives in 
functional analysis of the HERV-LTRs. It may be interesting to know that pBL-HERV-L 
and pEGFP-HERV-H-H6 transgenic rabbits have been produced (Agrobiogen GmbH, 
Hilgertshausen, Germany) to also consider species specific aspects of transgene 
expression. This work will be displayed in the dissertation of Zoltan Hubbes at the 
Department of Molecular Animal Breeding/LMU Munich. The gene construct pBL-
HERV-L will be investigated in additional transgenic mouse lines. Indication that the 
HERV-H-H6 LTR regulates gene expression in a tissue-specific manner renders this LTR 
especially interesting for further studies. 
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6 SUMMARY 
 
Generation of Transgenic Mice to Evaluate Promoter Activity and Specificity of two 
Human Endogenous Retrovirus Long Terminal Repeats 
 
Human Endogenous Retrovirus Long Terminal Repeats (HERV-LTRs) comprise 1.8% of 
the human genome (52.7 Mb). These sequences contain all the signal structures necessary 
for the regulation of gene transcription, such as promoters, enhancers and transcription 
factor binding sites. There is evidence that HERV-LTRs regulate gene expression in 
tissue-specific manner. This potential could be used to drive the expression of therapeutic 
genes, delivered by retroviral vector systems, in a safe and efficient manner. 
 
The HERV-H-H6 LTR and the HERV-L LTR were chosen for the generation of 
transgenic mice. Their promoter activity and specificity had prior been tested in a 
luciferase expression vector in vitro (Schoen et al., 2001). HERV-L was cloned into a 
luciferase expression vector and HERV-H-H6 was inserted into a enhanced green 
fluorescent protein (EGFP) expression vector. Transgenic mice were generated by DNA-
microinjection into pronuclei of zygotes. One pBL-HERV-L transgenic line and four 
pEGFP-HERV-H-H6 transgenic lines were established and analyzed. While the HERV-L 
promoter was not active in transgenic animals, pEGFP-HERV-H-H6 was expressed in 
gonads of mice of two transgenic lines. As only a single, non-expressing transgenic line 
was available, HERV-L promoter activity and specificity could not be evaluated. 
Additional transgenic lines have to be established. Expression level and pattern of the 
HERV-H-H6 promoter indicate specificity for gonad tissue. Whether the HERV-H-H6 
promoter activity is linked to steroid production in cells remains to be clarified. 
 
Evaluating promoter activity in transgenic mice in two different expression vectors is not 
exclusively about the promoters, but also involves knowledge about the reporter genes. 
Advantages and limits of current applications of both luciferase and EGFP (with focus on 
the EGFP gene) are described in REVIEW OF THE LITERATURE. The conjunction of 
EGFP with the HERV-H-H6 promoter is to be seen critically, as all published methods 
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for detection of EGFP in mice are described with EGFP linked to strong promoters. 
Problems like autofluorescence in fluorescence microscopy might be encountered when 
weaker promoters, such as HERV-LTRs, drive EGFP expression.
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7 ZUSAMMENFASSUNG 
 
Untersuchungen zur Promotor-Aktivität und –Spezifität von zwei Long Terminal Repeats 
humaner endogener Retroviren in transgenen Mäusen 
 
1.8% des humanen Genoms bestehen aus Long Terminal Repeats Humaner Endogener 
Retroviren (HERV-LTRs). Solche Sequenzen enthalten alle Strukturen, die für die 
Regulierung von Transkription benötigt werden: Promotoren, Enhancer and 
Bindungsstellen für Transkriptionsfaktoren. Es gibt Hinweise, daß HERV-LTRs die 
Expression von Genen gewebespezifisch regulieren können. Eingebaut in retrovirale 
Genfähren, könnten HERV-LTRs therapeutische Gene sicher und effizient aktivieren. 
 
Zur Generierung transgener Mäuse wurden der HERV-H-H6 LTR und der HERV-L LTR 
ausgewählt. Deren Promoter Eigenschaften, wie Aktivität und Gewebespezifität, waren 
bereits in vitro untersucht worden (Schoen et al., 2001). Der HERV-L LTR wurde in 
einen Luciferase Expressionsvektor und der HERV-H-H6 LTR in einen Enhanced Green 
Fluorescent Protein (EGFP) Expressionsvektor kloniert. Transgene Mäuse enstanden 
durch DNA-Mikroinjektion in den Vorkern von Zygoten. Eine pBL-HERV-L transgene 
Linie und vier pEGFP-HERV-H-H6 transgene Linien wurden gezüchtet und auf 
Integration sowie Expression der Genkonstrukte untersucht. Während der HERV-L 
Promoter keine Aktivität zeigte, war Expression von pEGFP-HERV-H-H6 in 
Keimdrüsen von Mäusen aus zwei transgenen Linien nachweisbar. Da für das 
Genkonstrukt pBL-HERV-L nur eine einzige, nicht-exprimierende transgene Linie 
aufgebaut werden konnte, können keine Aussagen über die Aktivität und 
Gewebespezifität des HERV-L Promoters getroffen werden. Zu diesem Zwecke müssten 
weitere pBL-HERV-L transgene Linien untersucht werden. Das Expressionsmuster des 
pEGFP-HERV-H-H6 Genkonstruktes, weißt auf eine mögliche Gewebespezifität für 
Keimdrüsen hin. Eine eventuelle Verknüpfung der Aktivität des HERV-H-H6 LTRs mit 
der Produktion von Steroidhormonen müsste weitergehend geklärt werden. 
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Da in dieser Arbeit zwei unterschiedliche Reportergen Systeme in der Maus angewandt 
wurden, sind im Literaturteil Vorteile und Einschränkungen von aktuellen 
Nachweisverfahren beider Reportergene, mit Schwerpunkt EGFP, in Mausgewebe 
zusammengefasst. Die Verbindung von EGFP mit dem HERV-H-H6 Promoter ist als 
kritisch zu beurteilen: Alle beschriebenen Nachweisverfahren für EGFP in der Maus 
gründen auf Mausmodellen, in denen das EGFP von einem starken Promoter kontrolliert 
wurde. Bei potenziell schwächeren Promotoren, wie HERV-LTRs, können Probleme 
auftreten, wie z.B. Autofluoreszenz bei der Fluoreszenzmikroskopie. 
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